. Au and . Ames, UT est localisé dans l'aorte thoracique, 1999.

. Matsushita, En revanche, le récepteur est très faiblement exprimé voire absent dans les veines caves, ainsi que dans les artères pulmonaires et coronaires, 1999.

. Maguire, , 2008.

. Gartlon, A l'image de l'UII, l'expression de l'UT est particulièrement importante au niveau rénal chez le Rat, 2001.

. Hirose, L'UT est aussi présent dans le système endocrinien, notamment dans l'hypophyse, le pancréas ou la glande surrénale chez l'Homme, 1999.

(. Souris and . Elshourbagy, Dans une moindre mesure, des niveaux d'ARNm ont été détectés chez le Rat et l'Homme dans le testicule et le corps caverneux, 2001.

&. Bianca, , 2006.

;. Daurade and . Kalamarz-kubiak, Enfin, d'autres tissus périphériques présentent des niveaux d'expression significatifs d'UT, variables d'une espèce à l'autre (Tab, vol.8, 2014.

R. Batuwangala, M. S. Calo, G. Guerrini, R. Ng, L. L. Mcdonald et al., Desensitisation of native and recombinant human urotensin-II receptors, Naunyn-Schmiedeberg's archives of pharmacology, vol.380, pp.451-457, 2009.

C. Beadle, M. C. Assanah, P. Monzo, R. Vallee, S. S. Rosenfeld et al., The role of myosin II in glioma invasion of the brain, Molecular biology of the cell, vol.19, pp.3357-3368, 2008.

D. J. Behm, N. V. Aiyar, A. R. Olzinski, J. J. Mcatee, M. A. Hilfiker et al., GSK1562590, a slowly dissociating urotensin-II receptor antagonist, exhibits prolonged pharmacodynamic activity ex vivo, British journal of pharmacology, vol.161, pp.207-228, 2010.

D. J. Behm, C. P. Doe, D. G. Johns, K. Maniscalco, G. P. Stankus et al., Urotensin-II: a novel systemic hypertensive factor in the cat, Naunyn-Schmiedeberg's archives of pharmacology, vol.369, pp.274-280, 2004.

D. J. Behm, C. L. Herold, V. Camarda, N. V. Aiyar, and S. A. Douglas, Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors, European journal of pharmacology, vol.492, pp.113-116, 2004.

D. J. Behm, C. L. Herold, E. H. Ohlstein, S. D. Knight, D. Dhanak et al., Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist, British journal of pharmacology, vol.137, pp.449-458, 2002.

D. J. Behm, J. J. Mcatee, J. W. Dodson, M. J. Neeb, H. E. Fries et al., Palosuran inhibits binding to primate UT receptors in cell membranes but demonstrates differential activity in intact cells and vascular tissues, British journal of pharmacology, vol.155, pp.374-386, 2008.

D. J. Behm, G. Stankus, C. P. Doe, R. N. Willette, H. M. Sarau et al., The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems, British journal of pharmacology, vol.148, pp.173-190, 2006.

L. Bello, M. Francolini, P. Marthyn, J. Zhang, R. S. Carroll et al., Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery, Neurosurgery, vol.49, pp.380-389, 2001.

S. Benvenuti and P. M. Comoglio, The MET receptor tyrosine kinase in invasion and metastasis, Journal of cellular physiology, vol.213, pp.316-325, 2007.

C. Berenguer-daize, F. Boudouresque, C. Bastide, A. Tounsi, Z. Benyahia et al., Adrenomedullin blockade suppresses growth of human hormone-independent prostate tumor xenograft in mice, Clinical cancer research, vol.19, pp.6138-6150, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01460433

J. D. Berlin, Targeting vascular endothelial growth factor in colorectal cancer, Oncology, vol.16, pp.13-15, 2002.

H. A. Bern and K. Lederis, A reference preparation for the study of active substances in the caudal neurosecretory system of teleosts, The Journal of endocrinology, vol.45, 1969.

L. Bethke, E. Webb, A. Murray, M. Schoemaker, C. Johansen et al., Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma, Human molecular genetics, vol.17, pp.800-805, 2008.

K. P. Bhat, V. Balasubramaniyan, B. Vaillant, R. Ezhilarasan, K. Hummelink et al., Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma, Cancer cell, vol.24, pp.331-346, 2013.

R. Bianca, E. Mitidieri, F. Fusco, D. 'aiuto, E. Grieco et al., Endogenous urotensin II selectively modulates erectile function through eNOS, PloS one, vol.7, p.31019, 2012.

M. Birker-robaczewska, C. Boukhadra, R. Studer, C. Mueller, C. Binkert et al., The expression of urotensin II receptor (U2R) is up-regulated by interferon-gamma, Journal of receptor and signal transduction research, vol.23, pp.289-305, 2003.

J. Blasiak, G. Petrovski, Z. Vereb, A. Facsko, and K. Kaarniranta, Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration, p.768026, 2014.

J. M. Blesa, S. B. Molla, M. F. Esparcia, J. M. Ortells, M. P. Godoy et al., Durable complete remission of a brainstem glioma treated with a combination of bevacizumab and cetuximab, Case reports in oncology, vol.5, pp.676-681, 2012.

O. Bogler, H. J. Huang, P. Kleihues, and W. K. Cavenee, The p53 gene and its role in human brain tumors, Glia, vol.15, pp.308-327, 1995.

F. Bohm and J. Pernow, Urotensin II evokes potent vasoconstriction in humans in vivo, British journal of pharmacology, vol.135, pp.25-27, 2002.

B. Boivin, D. Chevalier, L. R. Villeneuve, E. Rousseau, and B. G. Allen, Functional endothelin receptors are present on nuclei in cardiac ventricular myocytes, The Journal of biological chemistry, vol.278, pp.29153-29163, 2003.

S. Boivin, L. Guilhaudis, I. Milazzo, H. Oulyadi, D. Davoust et al., Characterization of urotensin-II receptor structural domains involved in the recognition of U-II, URP, and urantide, Biochemistry, vol.45, pp.5993-6002, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-00820020

S. Boivin, I. Segalas-milazzo, L. Guilhaudis, H. Oulyadi, A. Fournier et al., Solution structure of urotensin-II receptor extracellular loop III and characterization of its interaction with urotensin-II, Peptides, vol.29, pp.700-710, 2008.
URL : https://hal.archives-ouvertes.fr/hal-02352152

B. C. Bornhauser and D. Lindholm, MSAP enhances migration of C6 glioma cells through phosphorylation of the myosin regulatory light chain, Cellular and molecular life sciences, vol.62, pp.1260-1266, 2005.

F. E. Bottrill, S. A. Douglas, C. R. Hiley, and R. White, Human urotensin-II is an endotheliumdependent vasodilator in rat small arteries, British journal of pharmacology, vol.130, pp.1865-1870, 2000.

A. A. Boucard, S. S. Sauve, G. G. Escher, E. Leduc, and R. , Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain, The Biochemical journal, vol.370, pp.829-838, 2003.

N. Bousette, F. Hu, E. H. Ohlstein, D. Dhanak, S. A. Douglas et al., Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation, Journal of molecular and cellular cardiology, vol.41, pp.285-295, 2006.

N. Bousette, L. Patel, S. A. Douglas, E. H. Ohlstein, and A. Giaid, Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta, Atherosclerosis, vol.176, pp.117-123, 2004.

N. Bousette, J. Pottinger, W. Ramli, E. H. Ohlstein, D. Dhanak et al., Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease, Peptides, vol.27, pp.2919-2926, 2006.

C. P. Bracken, M. L. Whitelaw, and D. J. Peet, The hypoxia-inducible factors: key transcriptional regulators of hypoxic responses, Cellular and molecular life sciences, vol.60, pp.1376-1393, 2003.

D. J. Brat, A. A. Castellano-sanchez, S. B. Hunter, M. Pecot, C. Cohen et al., Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population, Cancer research, vol.64, pp.920-927, 2004.

S. Brem, R. Cotran, and J. Folkman, Tumor angiogenesis: a quantitative method for histologic grading, Journal of the National Cancer Institute, vol.48, pp.347-356, 1972.

A. Calogero, E. Pavoni, T. Gramaglia, D. 'amati, G. Ragona et al., Altered expression of alpha-dystroglycan subunit in human gliomas, Cancer biology & therapy, vol.5, pp.441-448, 2006.

V. Camarda, R. Guerrini, E. Kostenis, A. Rizzi, G. Calo et al., A new ligand for the urotensin II receptor, British journal of pharmacology, vol.137, pp.311-314, 2002.

V. Camarda, W. Song, E. Marzola, M. Spagnol, R. Guerrini et al., Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors, European journal of pharmacology, vol.498, pp.83-86, 2004.

V. Camarda, M. Spagnol, W. Song, R. Vergura, A. L. Roth et al., In vitro and in vivo pharmacological characterization of the novel UT receptor ligand, British journal of pharmacology, vol.147, pp.92-100, 2006.

P. Carmeliet, Angiogenesis in life, disease and medicine, Nature, vol.438, pp.932-936, 2005.

A. Carotenuto, L. Auriemma, F. Merlino, A. M. Yousif, D. Marasco et al., Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor, Journal of medicinal chemistry, vol.57, pp.5965-5974, 2014.

A. Carotenuto, P. Grieco, P. Campiglia, E. Novellino, and P. Rovero, Unraveling the active conformation of urotensin II, Journal of medicinal chemistry, vol.47, pp.1652-1661, 2004.

D. O. Carpenter and C. Sage, Setting prudent public health policy for electromagnetic field exposures, Reviews on environmental health, vol.23, pp.91-117, 2008.

A. F. Carpentier, D. Ferrari, O. Bailon, R. Ursu, C. Banissi et al., Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients, European journal of neurology, vol.19, pp.1337-1342, 2012.

H. Castel, M. Diallo, D. Chatenet, J. Leprince, L. Desrues et al., Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes, Journal of neurochemistry, vol.99, pp.582-595, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01960748

H. H. Chao, L. C. Sung, C. H. Chen, J. C. Liu, J. J. Chen et al., Lycopene inhibits urotensin-II-induced cardiomyocyte hypertrophy in neonatal rat cardiomyocytes, p.724670, 2014.

D. Chaponis, J. W. Barnes, J. L. Dellagatta, S. Kesari, E. Fast et al., Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas, Journal of neuro-oncology, vol.104, pp.179-189, 2011.

N. A. Charles, E. C. Holland, R. Gilbertson, R. Glass, and H. Kettenmann, The brain tumor microenvironment, Glia, vol.59, pp.1169-1180, 2011.

N. Chartrel, J. M. Conlon, C. F. Braun, B. Waugh, D. Vallarino et al., Urotensin II in the central nervous system of the frog Rana ridibunda: immunohistochemical localization and biochemical characterization, The Journal of comparative neurology, vol.364, pp.324-339, 1996.

D. Chatenet, C. Dubessy, J. Leprince, C. Boularan, L. Carlier et al., Structure-activity relationships and structural conformation of a novel urotensin II-related peptide, Peptides, vol.25, pp.1819-1830, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01960815

D. Chatenet, B. Folch, D. Feytens, M. Letourneau, D. Tourwe et al., Development and pharmacological characterization of conformationally constrained urotensin II-related peptide agonists, Journal of medicinal chemistry, vol.56, pp.9612-9622, 2013.
URL : https://hal.archives-ouvertes.fr/pasteur-01130814

D. Chatenet, T. T. Nguyen, M. Letourneau, and A. Fournier, Update on the urotensinergic system: new trends in receptor localization, activation, and drug design, Frontiers in endocrinology, vol.3, p.174, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-01001636

V. P. Chauhan, J. D. Martin, H. Liu, D. A. Lacorre, S. R. Jain et al., Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels, Nature communications, vol.4, p.2516, 2013.

C. Chen, R. Huang, A. Maclean, A. Muzikansky, S. Mukundan et al., Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival, Journal of neuro-oncology, vol.115, pp.267-276, 2013.

X. Chen, J. Fang, S. Wang, H. Liu, X. Du et al., A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells, Oncotarget, vol.5, pp.1955-1968, 2014.

Y. Chen, M. Zhao, X. Liu, W. Yao, J. Yang et al., Urotensin II receptor in the rat airway smooth muscle and its effect on the rat airway smooth muscle cells proliferation, Chinese medical sciences journal, vol.16, pp.231-235, 2001.

Y. L. Chen, J. C. Liu, S. H. Loh, C. H. Chen, C. Y. Hong et al., Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts, European journal of pharmacology, vol.593, pp.24-29, 2008.

Y. L. Chen, S. H. Loh, J. J. Chen, and C. S. Tsai, Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK, European journal of pharmacology, vol.680, pp.88-94, 2012.

Z. Chen, J. Xu, Y. Ye, Y. Li, H. Gong et al., Urotensin II inhibited the proliferation of cardiac side population cells in mice during pressure overload by JNK-LRP6 signalling, Journal of cellular and molecular medicine, vol.18, pp.852-862, 2014.

Z. W. Chen, Q. Yang, Y. Huang, L. Fan, X. W. Li et al., Human urotensin II in internal mammary and radial arteries of patients undergoing coronary surgery, Vascular pharmacology, vol.52, pp.70-76, 2010.

Y. Cheng and K. Paz, Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications, The investigational drugs journal, vol.11, pp.46-56, 2008.

J. Cheriyan, T. J. Burton, T. J. Bradley, S. M. Wallace, K. M. Maki-petaja et al., The effects of urotensin II and urantide on forearm blood flow and systemic haemodynamics in humans, British journal of clinical pharmacology, vol.68, pp.518-523, 2009.

B. M. Cheung, R. Leung, Y. B. Man, and L. Y. Wong, Plasma concentration of urotensin II is raised in hypertension, Journal of hypertension, vol.22, pp.1341-1344, 2004.

P. Chinnaiyan, M. Won, P. Y. Wen, A. M. Rojiani, M. Wendland et al., RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma, International journal of radiation oncology, vol.86, pp.880-884, 2013.

O. Chinot, P. Soulier, and M. Frenay, , 2010.

, Neuro-Chirurgie, vol.56, pp.491-498

C. Z. Chiu, B. W. Wang, and K. G. Shyu, Angiotensin II and the JNK pathway mediate urotensin II expression in response to hypoxia in rat cardiomyocytes, The Journal of endocrinology, vol.220, pp.233-246, 2014.

H. Cho, E. Ackerstaff, S. Carlin, M. E. Lupu, Y. Wang et al., Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia, Neoplasia, vol.11, pp.247-259, 2009.

J. G. Christensen, P. W. Vincent, W. D. Klohs, D. W. Fry, W. R. Leopold et al., Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor, Molecular cancer therapeutics, vol.4, pp.938-947, 2005.

G. Ciriello, E. Cerami, C. Sander, and N. Schultz, Mutual exclusivity analysis identifies oncogenic network modules, Genome research, vol.22, pp.398-406, 2012.

P. Cirillo, D. Rosa, S. Pacileo, M. Gargiulo, A. Angri et al., Human urotensin II induces tissue factor and cellular adhesion molecules expression in human coronary endothelial cells: an emerging role for urotensin II in cardiovascular disease, Journal of thrombosis and haemostasis, vol.6, pp.726-736, 2008.

S. D. Clark, H. P. Nothacker, Z. Wang, Y. Saito, F. M. Leslie et al., The urotensin II receptor is expressed in the cholinergic mesopontine tegmentum of the rat, Brain research, vol.923, pp.120-127, 2001.

M. Clozel, C. Binkert, M. Birker-robaczewska, C. Boukhadra, S. S. Ding et al., -methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System, The Journal of pharmacology and experimental therapeutics, vol.311, issue.3, pp.204-212, 2004.

M. Clozel, P. Hess, C. Qiu, S. S. Ding, and M. Rey, The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats, The Journal of pharmacology and experimental therapeutics, vol.316, pp.1115-1121, 2006.

M. H. Cohen, Y. L. Shen, P. Keegan, and R. Pazdur, FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme, The oncologist, vol.14, pp.1131-1138, 2009.

S. E. Combs, D. Schulz-ertner, W. Roth, C. Herold-mende, J. Debus et al., In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab, International journal of radiation oncology, vol.68, pp.873-882, 2007.

J. M. Conlon, F. O'harte, D. D. Smith, M. C. Tonon, and H. Vaudry, Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda, Biochemical and biophysical research communications, vol.188, pp.578-583, 1992.

Y. Coulouarn, S. Jegou, H. Tostivint, H. Vaudry, and I. Lihrmann, Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors, FEBS letters, vol.457, pp.28-32, 1999.

V. G. Cooke, V. S. Lebleu, D. Keskin, Z. Khan, J. T. O'connell et al., Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway, Cancer cell, vol.21, pp.66-81, 2012.

Y. Coulouarn, I. Lihrmann, S. Jegou, Y. Anouar, H. Tostivint et al., Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord, Proceedings of the National Academy of Sciences of the United States of America, vol.95, pp.15803-15808, 1998.

C. Decaestecker, I. Camby, L. Gordower, O. Dewitte, P. Cras et al., Characterization of astroglial versus oligodendroglial phenotypes in glioblastomas by means of quantitative morphonuclear variables generated by computer-assisted microscopy, Journal of neuropathology and experimental neurology, vol.57, pp.791-802, 1998.

D. Vecchio, C. A. Li, G. Wong, and A. J. , Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas, Expert review of vaccines, vol.11, pp.133-144, 2012.

T. Demir, I. Turkbeyler, D. S. Kaplan, Y. Pehlivan, M. Orkmez et al., Effectiveness of palosuran in bleomycin-induced experimental scleroderma, Inflammation, vol.36, pp.75-79, 2013.

R. Di-villa-bianca, G. Cirino, E. Mitidieri, C. Coletta, G. Grassia et al., Urotensin II: a novel target in human corpus cavernosum, The journal of sexual medicine, vol.7, pp.1778-1786, 2010.

T. Demuth and M. E. Berens, Molecular mechanisms of glioma cell migration and invasion, Journal of neuro-oncology, vol.70, pp.217-228, 2004.

B. J. Denny, R. T. Wheelhouse, M. F. Stevens, L. L. Tsang, and J. A. Slack, NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA, Biochemistry, vol.33, pp.9045-9051, 1994.

R. Dermietzel and D. C. Spray, Gap junctions in the brain: where, what type, how many and why?, Trends in neurosciences, vol.16, pp.186-192, 1993.

A. Desjardins, D. A. Reardon, K. B. Peters, S. Threatt, A. D. Coan et al., A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma, Journal of neuro-oncology, vol.105, pp.601-606, 2011.

L. Desrues, T. Lefebvre, M. Diallo, P. Gandolfo, J. Leprince et al., Effect of GABA A receptor activation on UT-coupled signaling pathways in rat cortical astrocytes, Peptides, vol.29, pp.727-734, 2008.

L. Desrues, T. Lefebvre, C. Lecointre, M. T. Schouft, J. Leprince et al., Down-regulation of GABA(A) receptor via promiscuity with the vasoactive peptide urotensin II receptor. Potential involvement in astrocyte plasticity, PloS one, vol.7, p.36319, 2012.
URL : https://hal.archives-ouvertes.fr/hal-02294501

G. A. Deuchar, I. Morecroft, Y. Dempsie, N. Herold, M. Nilsen et al., The in vivo effects of human urotensin II in the rabbit and rat pulmonary circulation: effects of experimental pulmonary hypertension, European journal of pharmacology, vol.537, pp.135-142, 2006.

M. Diallo, M. Jarry, L. Desrues, H. Castel, D. Chatenet et al., Orn5]URP acts as a pure antagonist of urotensinergic receptors in rat cortical astrocytes, Peptides, vol.29, pp.813-819, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01962707

A. Diaz-miqueli and G. S. Martinez, Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities, OncoTargets and therapy, vol.6, pp.931-942, 2013.

. Di-cristofori, G. Carrabba, G. Lanfranchi, C. Menghetti, P. Rampini et al., Continuous tamoxifen and dose-dense temozolomide in recurrent glioblastoma, Anticancer research, vol.33, pp.3383-3389, 2013.

I. Diebold, A. Petry, M. Burger, J. Hess, and A. Gorlach, NOX4 mediates activation of FoxO3a and matrix metalloproteinase-2 expression by urotensin-II, Molecular biology of the cell, vol.22, pp.4424-4434, 2011.

I. Diebold, A. Petry, K. Sabrane, T. Djordjevic, J. Hess et al., The HIF1 target gene NOX2 promotes angiogenesis through urotensin-II, Journal of cell science, vol.125, pp.956-964, 2012.

T. Djordjevic, R. S. Belaiba, S. Bonello, J. Pfeilschifter, J. Hess et al., Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells, Arteriosclerosis, thrombosis, and vascular biology, vol.25, pp.519-525, 2005.

N. D. Doan, T. T. Nguyen, M. Letourneau, K. Turcotte, A. Fournier et al., Biochemical and pharmacological characterization of nuclear urotensin-II binding sites in rat heart, British journal of pharmacology, vol.166, pp.243-257, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-00818552

L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, R. Kim et al., Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas, Neurology, vol.67, pp.156-158, 2006.

T. A. Dolecek, J. M. Propp, N. E. Stroup, and C. Kruchko, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009, vol.14, pp.1-49, 2012.

J. C. Do-rego, D. Chatenet, M. H. Orta, B. Naudin, L. Cudennec et al., Behavioral effects of urotensin-II centrally administered in mice, Psychopharmacology, vol.183, pp.103-117, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01962710

S. A. Douglas, D. J. Ashton, C. F. Sauermelch, R. W. Coatney, D. H. Ohlstein et al., Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate, Journal of cardiovascular pharmacology, vol.36, pp.163-166, 2000.

S. A. Douglas, D. J. Behm, N. V. Aiyar, D. Naselsky, J. Disa et al., Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375, British journal of pharmacology, vol.145, pp.620-635, 2005.

S. A. Douglas, D. Dhanak, and D. G. Johns, From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function, Trends in pharmacological sciences, vol.25, pp.76-85, 2004.

S. A. Douglas, D. Naselsky, Z. Ao, J. Disa, C. L. Herold et al., Identification and pharmacological characterization of native, functional human urotensin-II receptors in rhabdomyosarcoma cell lines, British journal of pharmacology, vol.142, pp.921-932, 2004.

S. A. Douglas and E. H. Ohlstein, Human urotensin-II, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease, Trends in cardiovascular medicine, vol.10, pp.229-237, 2000.

S. A. Douglas, L. Tayara, E. H. Ohlstein, N. Halawa, and A. Giaid, Congestive heart failure and expression of myocardial urotensin II, Lancet, vol.359, pp.1990-1997, 2002.

T. Dschietzig, C. Bartsch, R. Pregla, H. R. Zurbrugg, F. P. Armbruster et al., Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure, Regulatory peptides, vol.110, pp.33-38, 2002.

C. Dubessy, D. Cartier, B. Lectez, C. Bucharles, N. Chartrel et al., Characterization of urotensin II, distribution of urotensin II, urotensin II-related peptide and UT receptor mRNAs in mouse: evidence of urotensin II at the neuromuscular junction, Journal of neurochemistry, vol.107, pp.361-374, 2008.
URL : https://hal.archives-ouvertes.fr/hal-01962726

P. Duenisch, R. Reichart, U. Mueller, M. Brodhun, R. Bjerkvig et al., Neural cell adhesion molecule isoform 140 declines with rise of WHO grade in human gliomas and serves as indicator for the invasion zone of multiform glioblastomas and brain metastases, Journal of cancer research and clinical oncology, vol.137, pp.399-414, 2011.

C. Dufes, C. Alleaume, A. Montoni, J. C. Olivier, and J. M. Muller, Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro, Journal of molecular neuroscience, vol.21, pp.91-102, 2003.

S. L. Dun, G. C. Brailoiu, J. Yang, J. K. Chang, and N. J. Dun, Urotensin II-immunoreactivity in the brainstem and spinal cord of the rat, Neuroscience letters, vol.305, pp.9-12, 2001.

J. Folkman, Tumor angiogenesis: therapeutic implications, The New England journal of medicine, vol.285, pp.1182-1186, 1971.

A. P. Fontes-sousa, C. Bras-silva, A. L. Pires, D. Monteiro-sousa, and A. F. Leite-moreira, Urotensin II acutely increases myocardial length and distensibility: potential implications for diastolic function and ventricular remodeling, Naunyn-Schmiedeberg's archives of pharmacology, vol.376, pp.107-115, 2007.

R. Francescone, S. Scully, B. Bentley, W. Yan, S. L. Taylor et al., Glioblastoma-derived tumor cells induce vasculogenic mimicry through Flk-1 protein activation, The Journal of biological chemistry, vol.287, pp.24821-24831, 2012.

R. Franco, S. Zappavigna, V. Gigantino, A. Luce, M. Cantile et al., Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion, Journal of experimental & clinical cancer research, vol.33, p.48, 2014.

H. S. Friedman, R. E. Mclendon, T. Kerby, M. Dugan, S. H. Bigner et al., DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma, Journal of clinical oncology, vol.16, pp.3851-3857, 1998.

F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment, Genes & development, vol.21, pp.2683-2710, 2007.

G. ,

P. Gabelloni, E. Da-pozzo, S. Bendinelli, B. Costa, E. Nuti et al., Inhibition of metalloproteinases derived from tumours: new insights in the treatment of human glioblastoma, Neuroscience, vol.168, pp.514-522, 2010.

K. Gaengel, C. Niaudet, K. Hagikura, B. Lavina, L. Muhl et al., The sphingosine-1-phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE-cadherin and VEGFR2, Developmental cell, vol.23, pp.587-599, 2012.

S. Gao, Y. B. Oh, B. M. Park, W. H. Park, and S. H. Kim, Urotensin II protects ischemic reperfusion injury of hearts through ROS and antioxidant pathway, Peptides, vol.36, pp.199-205, 2012.

S. Gao, Y. B. Oh, A. Shah, W. H. Park, M. J. Chung et al., Urotensin II receptor antagonist attenuates monocrotaline-induced cardiac hypertrophy in rats, American journal of physiology Heart and circulatory physiology, vol.299, pp.1782-1789, 2010.

S. M. Gardiner, J. E. March, P. A. Kemp, A. P. Davenport, and T. Bennett, Depressor and regionally-selective vasodilator effects of human and rat urotensin II in conscious rats, British journal of pharmacology, vol.132, pp.1625-1629, 2001.

J. Gartlon, F. Parker, D. C. Harrison, S. A. Douglas, T. E. Ashmeade et al., Central effects of urotensin-II following ICV administration in rats, Psychopharmacology, vol.155, pp.426-433, 2001.

G. Gendron, B. Simard, F. Gobeil, P. Sirois, D. 'orleans-juste et al., Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats, Canadian journal of physiology and pharmacology, vol.82, pp.16-21, 2004.

B. Geoerger, M. W. Kieran, S. Grupp, D. Perek, J. Clancy et al., Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma, European journal of cancer, vol.48, pp.253-262, 2012.

E. R. Gerstner, A. F. Eichler, S. R. Plotkin, J. Drappatz, C. L. Doyle et al., Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing antiepileptic drugs and standard radiation and temozolomide, Journal of neuro-oncology, vol.103, pp.325-332, 2011.

A. Gibson, Complex effects of Gillichthys urotensin II on rat aortic strips, British journal of pharmacology, vol.91, pp.205-212, 1987.

A. Gibson, S. Conyers, and H. A. Bern, The influence of urotensin II on calcium flux in rat aorta, The Journal of pharmacy and pharmacology, vol.40, pp.893-895, 1988.

M. R. Gilbert and F. F. Lang, Management of patients with low-grade gliomas, Neurologic clinics, vol.25, pp.1073-1088, 2007.

M. C. Gingras, E. Roussel, J. M. Bruner, C. D. Branch, and R. P. Moser, Comparison of cell adhesion molecule expression between glioblastoma multiforme and autologous normal brain tissue, Journal of neuroimmunology, vol.57, pp.143-153, 1995.

L. Giuliani, L. Lenzini, M. Antonello, E. Aldighieri, A. S. Belloni et al., Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism, The Journal of clinical endocrinology and metabolism, vol.94, pp.684-690, 2009.

S. Goel, D. G. Duda, L. Xu, L. L. Munn, Y. Boucher et al., Normalization of the vasculature for treatment of cancer and other diseases, Physiological reviews, vol.91, pp.1071-1121, 2011.

H. Gong, Y. X. Wang, Y. Z. Zhu, W. W. Wang, M. J. Wang et al., Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat, Journal of applied physiology, vol.97, pp.2228-2235, 2004.

Y. S. Gong, X. F. Fan, X. M. Wu, Y. Q. Gao, L. G. Hu et al., Dynamic changes of urotensin II receptor in pulmonary artery and arterioles of rats chronically exposed to hypoxia-hypercapnia, 2005.

, Chinese journal of applied physiology, vol.21, pp.377-381

G. C. Gonzalez, M. Martinez-padron, K. Lederis, and K. Lukowiak, Distribution and coexistence of urotensin I and urotensin II peptides in the cerebral ganglia of Aplysia californica, Peptides, vol.13, pp.695-703, 1992.

J. Gonzalez, N. Valls, R. Brito, and R. R. , Essential hypertension and oxidative stress: New insights, World journal of cardiology, vol.6, pp.353-366, 2014.

D. A. Goodenough, J. A. Goliger, and D. L. Paul, Connexins, connexons, and intercellular communication, Annual review of biochemistry, vol.65, pp.475-502, 1996.

P. S. Gould, M. Gu, J. Liao, S. Ahmad, M. J. Cudmore et al., Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia, Hypertension, vol.56, pp.172-178, 2010.

E. G. Grau, R. S. Nishioka, and H. A. Bern, Effects of somatostatin and urotensin II on tilapia pituitary prolactin release and interactions between somatostatin, osmotic pressure Ca ++ , and adenosine 3',5'-monophosphate in prolactin release in vitro, Endocrinology, vol.110, pp.910-915, 1982.

P. Grieco, A. Carotenuto, P. Campiglia, E. Zampelli, R. Patacchini et al., A new, potent urotensin II receptor peptide agonist containing a Pen residue at the disulfide bridge, Journal of medicinal chemistry, vol.45, pp.4391-4394, 2002.

P. Grieco, R. Franco, G. Bozzuto, L. Toccacieli, A. Sgambato et al., Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells, Journal of cellular biochemistry, vol.112, pp.341-353, 2011.

P. G. Gritsenko, O. Ilina, and P. Friedl, Interstitial guidance of cancer invasion, The Journal of pathology, vol.226, pp.185-199, 2012.

M. Groblewska, M. Siewko, B. Mroczko, and M. Szmitkowski, The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer, Folia histochemica et cytobiologica, vol.50, pp.12-19, 2012.

M. D. Groves, V. K. Puduvalli, C. A. Conrad, M. R. Gilbert, W. K. Yung et al., Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status, Journal of neuro-oncology, vol.80, pp.83-90, 2006.

D. Gruson, A. Ginion, N. Decroly, P. Lause, J. L. Vanoverschelde et al., Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3beta signaling pathway, Peptides, vol.31, pp.1326-1333, 2010.

D. Gruson, M. F. Rousseau, S. A. Ahn, F. Van-linden, and J. M. Ketelslegers, Circulating urotensin II levels in moderate to severe congestive heart failure: its relations with myocardial function and well established neurohormonal markers, Peptides, vol.27, pp.1527-1531, 2006.

Y. Gu, H. Wang, Y. Qin, Y. Zhang, W. Zhao et al., Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma, Molecular bioSystems, vol.9, pp.467-477, 2013.

V. Gubala, C. C. Lynam, R. Nooney, S. Hearty, B. Mcdonnell et al., Kinetics of immunoassays with particles as labels: effect of antibody coupling using dendrimers as linkers, The Analyst, vol.136, pp.2533-2541, 2011.

R. Guerrini, V. Camarda, E. Marzola, M. Arduin, G. Calo et al., Structure-activity relationship study on human urotensin II, Journal of peptide science, vol.11, pp.85-90, 2005.

D. Guidolin, G. Albertin, B. Oselladore, E. Sorato, P. Rebuffat et al., The pro-angiogenic activity of urotensin-II on human vascular endothelial cells involves ERK1/2 and PI3K signaling pathways, Regulatory peptides, vol.162, pp.26-32, 2010.

J. S. Guillamo, Anti-angiogenic strategies in glioblastoma, Revue neurologique, vol.167, pp.662-667, 2011.

H. ,

C. Hagemann, J. Anacker, R. I. Ernestus, and G. H. Vince, A complete compilation of matrix metalloproteinase expression in human malignant gliomas, World journal of clinical oncology, vol.3, pp.67-79, 2012.

A. Hara, M. Saegusa, T. Mikami, and I. Okayasu, Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival, Journal of clinical pathology, vol.54, pp.860-865, 2001.

L. Hardell, M. Carlberg, F. Soderqvist, K. H. Mild, and L. L. Morgan, Long-term use of cellular phones and brain tumours: increased risk associated with use for > or =10 years, Occupational and environmental medicine, vol.64, pp.626-632, 2007.

G. S. Hassan, F. Chouiali, T. Saito, F. Hu, S. A. Douglas et al., Effect of human urotensin-II infusion on hemodynamics and cardiac function, Canadian journal of physiology and pharmacology, vol.81, pp.125-128, 2003.

G. S. Hassan, S. A. Douglas, E. H. Ohlstein, and A. Giaid, Expression of urotensin-II in human coronary atherosclerosis, Peptides, vol.26, pp.2464-2472, 2005.

J. He, K. Mokhtari, M. Sanson, Y. Marie, M. Kujas et al., Glioblastomas with an oligodendroglial component: a pathological and molecular study, Journal of neuropathology and experimental neurology, vol.60, pp.863-871, 2001.

A. B. Heimberger, L. Y. Kong, M. Abou-ghazal, R. -. Ortiz, C. Yang et al., The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor, Clinical neurosurgery, vol.56, pp.98-106, 2009.

J. Heller, M. Schepke, M. Neef, R. Woitas, C. Rabe et al., Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension, Journal of hepatology, vol.37, pp.767-772, 2002.

G. Helmlinger, F. Yuan, M. Dellian, and R. K. Jain, Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation, Nature medicine, vol.3, pp.177-182, 1997.

S. P. Herbert, J. Y. Cheung, and D. Y. Stainier, Determination of endothelial stalk versus tip cell potential during angiogenesis by H2.0-like homeobox-1, Current biology, vol.22, pp.1789-1794, 2012.

M. Heringlake, T. Kox, O. Uzun, B. Will, L. Bahlmann et al., The relationship between urotensin II plasma immunoreactivity and left ventricular filling pressures in coronary artery disease, Regulatory peptides, vol.121, pp.129-136, 2004.

J. R. Hesselink, M. J. Barkovich, T. M. Seibert, N. Farid, K. A. Muller et al., Bevacizumab: radiation combination produces restricted diffusion on brain MRI, CNS oncology, vol.3, pp.329-335, 2014.

T. Hikosaka, T. Tsuruda, S. Nagata, K. Kuwasako, K. Tsuchiya et al., Adrenomedullin production is increased in colorectal adenocarcinomas; its relation to matrix metalloproteinase-9, Peptides, vol.32, pp.1825-1831, 2011.

D. A. Hilton, M. Penney, L. Pobereskin, H. Sanders, and S. Love, Histological indicators of prognosis in glioblastomas: retinoblastoma protein expression and oligodendroglial differentiation indicate improved survival, Histopathology, vol.44, pp.555-560, 2004.

T. Hirose, K. Takahashi, N. Mori, T. Nakayama, M. Kikuya et al., Increased expression of urotensin II, urotensin II-related peptide and urotensin II receptor mRNAs in the cardiovascular organs of hypertensive rats: comparison with endothelin-1, Peptides, vol.30, pp.1124-1129, 2009.

Y. Hirose, M. S. Berger, and R. O. Pieper, effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer research, vol.61, pp.1957-1963, 2001.

K. Hoang-xuan, A. Idbaih, K. Mokhtari, and M. Sanson, Bulletin du cancer, vol.92, pp.310-316, 2005.

J. Holash, P. C. Maisonpierre, D. Compton, P. Boland, C. R. Alexander et al., Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, vol.284, pp.1994-1998, 1999.

B. J. Holleran, I. Domazet, M. E. Beaulieu, L. P. Yan, G. Guillemette et al., Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor, Biochemical pharmacology, vol.77, pp.1374-1382, 2009.

B. D. Hopkins, B. Fine, N. Steinbach, M. Dendy, Z. Rapp et al., A secreted PTEN phosphatase that enters cells to alter signaling and survival, Science, vol.341, pp.399-402, 2013.

H. S. Huang, M. Nagane, C. K. Klingbeil, H. Lin, R. Nishikawa et al., The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling, The Journal of biological chemistry, vol.272, pp.2927-2935, 1997.

S. Huitron-resendiz, M. P. Kristensen, M. Sanchez-alavez, S. D. Clark, S. L. Grupke et al., Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons, The Journal of neuroscience, vol.25, pp.5465-5474, 2005.

M. Hursitoglu, T. Tukek, M. A. Cikrikcioglu, O. Kara, R. Kazancioglu et al., , 2012.

, Urotensin II levels in patients with chronic kidney disease and kidney transplants, Upsala journal of medical sciences, vol.117, pp.22-27

M. Iglewski and S. R. Grant, Urotensin II-induced signaling involved in proliferation of vascular smooth muscle cells, Vascular health and risk management, vol.6, pp.723-734, 2010.

M. L. Iruela-arispe and G. J. Beitel, Tubulogenesis. Development, vol.140, pp.2851-2855, 2013.

A. Ishihata, T. Ogaki, T. Aita, and Y. Katano, Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats, European journal of pharmacology, vol.523, pp.119-126, 2005.

N. Ishii, Y. Sawamura, M. Tada, D. M. Daub, R. C. Janzer et al., Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay, International journal of cancer, vol.76, pp.797-800, 1998.

H. Itoh and K. Lederis, Relationship of urotensin I induced vasodilatory action in rat thoracic aorta to Ca2+ regulation, Canadian journal of physiology and pharmacology, vol.65, pp.298-302, 1987.

F. M. Iwamoto, K. R. Lamborn, H. I. Robins, M. P. Mehta, S. M. Chang et al., Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02), Neurooncology, vol.12, pp.855-861, 2010.

S. Izumoto, T. Ohnishi, N. Arita, S. Hiraga, T. Taki et al., Gene expression of neural cell adhesion molecule L1 in malignant gliomas and biological significance of L1 in glioma invasion, Cancer research, vol.56, pp.1440-1444, 1996.

, J

R. D. Jager, W. F. Mieler, and J. W. Miller, Age-related macular degeneration, The New England journal of medicine, vol.358, pp.2606-2617, 2008.

P. P. Jani, H. Narayan, and L. L. Ng, The differential extraction and immunoluminometric assay of Urotensin II and Urotensin-related peptide in heart failure, Peptides, vol.40, pp.72-76, 2013.

E. T. Janson, Treatment of neuroendocrine tumors with somatostatin analogs, Pituitary, vol.9, pp.249-256, 2006.

M. Jarry, M. Diallo, C. Lecointre, L. Desrues, T. Tokay et al., The vasoactive peptides urotensin II and urotensin II-related peptide regulate astrocyte activity through common and distinct mechanisms: involvement in cell proliferation, The Biochemical journal, vol.428, pp.113-124, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00479207

M. Jeansson, A. Gawlik, G. Anderson, C. Li, D. Kerjaschki et al., Angiopoietin-1 is essential in mouse vasculature during development and in response to injury, The Journal of clinical investigation, vol.121, pp.2278-2289, 2011.

S. Jegou, D. Cartier, C. Dubessy, B. J. Gonzalez, D. Chatenet et al., Localization of the urotensin II receptor in the rat central nervous system, The Journal of comparative neurology, vol.495, pp.21-36, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01962761

R. L. Jensen, Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target, Journal of neuro-oncology, vol.92, pp.317-335, 2009.

D. Joh, B. J. Park, and Y. J. Lim, Radiation-induced glioblastoma multiforme in a remitted acute lymphocytic leukemia patient, Journal of Korean Neurosurgical Society, vol.50, pp.235-239, 2011.

D. G. Johns, Z. Ao, D. Naselsky, C. L. Herold, K. Maniscalco et al., Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators, Naunyn-Schmiedeberg's archives of pharmacology, vol.370, pp.238-250, 2004.

A. D. Joshi, W. Loilome, I. M. Siu, B. Tyler, G. L. Gallia et al., Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy, PloS one, vol.7, p.44372, 2012.

D. Joyal, T. Huynh, N. Aiyar, B. Guida, S. Douglas et al., Urotensin-II levels in acute coronary syndromes, International journal of cardiology, vol.108, pp.31-35, 2006.

Y. Jung, K. M. Joo, D. H. Seong, Y. L. Choi, D. S. Kong et al., Identification of prognostic biomarkers for glioblastomas using protein expression profiling, International journal of oncology, vol.40, pp.1122-1132, 2012.

W. A. Kinney, . Almond, . Hr, J. Qi, C. E. Smith et al., Structurefunction analysis of urotensin II and its use in the construction of a ligand-receptor working model, Angewandte Chemie, vol.41, pp.2940-2944, 2002.

P. Kleihues and H. Ohgaki, Primary and secondary glioblastomas: from concept to clinical diagnosis, Neuro-oncology, vol.1, pp.44-51, 1999.

A. W. Koch, T. Mathivet, B. Larrivee, R. K. Tong, J. Kowalski et al., Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B, vol.20, pp.33-46, 2011.

M. Y. Koh and G. Powis, Passing the baton: the HIF switch, Trends in biochemical sciences, vol.37, pp.364-372, 2012.

A. R. Kompa, W. G. Thomas, F. See, A. Tzanidis, R. D. Hannan et al., Cardiovascular role of urotensin II: effect of chronic infusion in the rat, Peptides, vol.25, pp.1783-1788, 2004.

T. N. Kreisl, S. Kotliarova, J. A. Butman, P. S. Albert, L. Kim et al., A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas, Neuro-oncology, vol.12, pp.181-189, 2010.

T. N. Kreisl, K. A. Mcneill, J. Sul, F. M. Iwamoto, J. Shih et al., A phase I/II trial of vandetanib for patients with recurrent malignant glioma, Neuro-oncology, vol.14, pp.1519-1526, 2012.

T. N. Kreisl, P. Smith, J. Sul, C. Salgado, F. M. Iwamoto et al., Continuous daily sunitinib for recurrent glioblastoma, Journal of neuro-oncology, vol.111, pp.41-48, 2013.

A. S. Kristof, Z. You, Y. S. Han, and A. Giaid, Protein expression of urotensin II, urotensinrelated peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis, Peptides, vol.31, pp.1511-1516, 2010.

D. A. Krueger, M. M. Care, K. Agricola, C. Tudor, M. Mays et al., Everolimus longterm safety and efficacy in subependymal giant cell astrocytoma, Neurology, vol.80, pp.574-580, 2013.

H. Krum and W. Kemp, Therapeutic potential of blockade of the urotensin II system in systemic hypertension, Current hypertension reports, vol.9, pp.53-58, 2007.

B. M. Ku, Y. K. Lee, J. Ryu, J. Y. Jeong, J. Choi et al., CHI3L1 (YKL-40) is expressed in human gliomas and regulates the invasion, growth and survival of glioma cells, International journal of cancer, vol.128, pp.1316-1326, 2011.

U. Lehner, A. Velic, R. Schroter, E. Schlatter, and A. Sindic, Ligands and signaling of the Gprotein-coupled receptor GPR14, expressed in human kidney cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, vol.20, pp.181-192, 2007.

A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. Mcdonald et al., Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease, British journal of anaesthesia, vol.102, pp.477-484, 2009.

E. Lescot, J. Sopkova-de-oliveira-santos, N. Colloc'h, R. J. Milazzo-segalas, I. Bureau et al., Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model, Proteins, vol.73, pp.173-184, 2008.

E. Lescot, J. Sopkova-de-oliveira-santos, C. Dubessy, H. Oulyadi, A. Lesnard et al., Definition of new pharmacophores for nonpeptide antagonists of human urotensin-II. Comparison with the 3D-structure of human urotensin-II and URP, Journal of chemical information and modeling, vol.47, pp.602-612, 2007.
URL : https://hal.archives-ouvertes.fr/hal-02179719

H. Li, J. Chen, M. He, X. H. Hui, B. W. Cai et al., Expression of CD147 and MMP-2 in human gliomas and its correlations with prognosis, Journal of Sichuan University Medical science edition, vol.38, pp.396-399, 2007.

J. L. Li, R. C. Sainson, W. Shi, R. Leek, L. S. Harrington et al., Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo, Cancer research, vol.67, pp.11244-11253, 2007.

K. L. Ligon, E. Huillard, S. Mehta, S. Kesari, H. Liu et al., Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma, Neuron, vol.53, pp.503-517, 2007.

F. R. Lima, S. A. Kahn, R. C. Soletti, D. Biasoli, T. Alves et al., Glioblastoma: therapeutic challenges, what lies ahead, Biochimica et biophysica acta, vol.1826, pp.338-349, 2012.

Y. Lin, T. Tsuchihashi, K. Matsumura, I. Abe, and M. Iida, Central cardiovascular action of urotensin II in conscious rats, Journal of hypertension, vol.21, pp.159-165, 2003.

Y. Lin, T. Tsuchihashi, K. Matsumura, M. Fukuhara, Y. Ohya et al., Central cardiovascular action of urotensin II in spontaneously hypertensive rats, Hypertension research, vol.26, pp.839-845, 2003.

P. Lindahl, M. Hellstrom, M. Kalen, and C. Betsholtz, Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice, Current opinion in lipidology, vol.9, pp.407-411, 1998.

J. J. Maguire, R. E. Kuc, M. J. Kleinz, and A. P. Davenport, Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: relevance to function, Peptides, vol.29, pp.735-742, 2008.

J. J. Maguire, R. E. Kuc, K. E. Wiley, M. J. Kleinz, and A. P. Davenport, Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries, Peptides, vol.25, pp.1767-1774, 2004.

F. Mallamaci, S. Cutrupi, P. Pizzini, G. Tripepi, and C. Zoccali, Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides, Journal of nephrology, vol.18, pp.727-732, 2005.

A. J. Maniotis, R. Folberg, A. Hess, E. A. Seftor, L. M. Gardner et al., Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry, The American journal of pathology, vol.155, pp.739-752, 1999.

M. Mannino and A. J. Chalmers, Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit, Molecular oncology, vol.5, pp.374-386, 2011.

A. Marchese, M. Heiber, T. Nguyen, H. H. Heng, V. R. Saldivia et al., Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors, Genomics, vol.29, pp.335-344, 1995.

J. Marco, E. M. Egido, R. Hernandez, and R. A. Silvestre, Evidence for endogenous urotensin-II as an inhibitor of insulin secretion. Study in the perfused rat pancreas, Peptides, vol.29, pp.852-858, 2008.

Y. Matsumoto, M. Abe, T. Watanabe, Y. Adachi, T. Yano et al., Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents, Neuroscience letters, vol.358, pp.99-102, 2004.

S. Matsusaka and I. Wakabayashi, Enhancement of vascular smooth muscle cell migration by urotensin II, Naunyn-Schmiedeberg's archives of pharmacology, vol.373, pp.381-386, 2006.

M. Matsushita, M. Shichiri, N. Fukai, N. Ozawa, T. Yoshimoto et al., Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology, vol.144, pp.1825-1831, 2003.

M. Matsushita, M. Shichiri, T. Imai, M. Iwashina, H. Tanaka et al., Coexpression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues, Journal of hypertension, vol.19, pp.2185-2190, 2001.

W. S. Mcdonough, A. Johansson, H. Joffee, A. Giese, and M. E. Berens, Gap junction intercellular communication in gliomas is inversely related to cell motility, International journal of developmental neuroscience, vol.17, pp.601-611, 1999.

B. P. Mckinley, A. M. Michalek, R. A. Fenstermaker, and R. J. Plunkett, The impact of age and sex on the incidence of glial tumors in New York state from 1976 to 1995, Journal of neurosurgery, vol.93, pp.932-939, 2000.

M. Mori, T. Sugo, M. Abe, Y. Shimomura, M. Kurihara et al., Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14), Biochemical and biophysical research communications, vol.265, pp.123-129, 1999.

N. Mori, T. Hirose, T. Nakayama, O. Ito, M. Kanazawa et al., Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure, Peptides, vol.30, pp.400-408, 2009.

R. Morimoto, F. Satoh, O. Murakami, K. Totsune, Y. Arai et al., Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues, Peptides, vol.29, pp.873-880, 2008.

P. G. Morris and L. E. Abrey, Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas, Targeted oncology, vol.5, pp.193-200, 2010.

A. Mosenkis, R. R. Kallem, T. M. Danoff, N. Aiyar, J. Bazeley et al., Renal impairment, hypertension and plasma urotensin II, Nephrology, dialysis, transplantation, vol.26, pp.609-614, 2011.

K. Motomura, M. Mittelbronn, W. Paulus, B. Brokinkel, K. Keyvani et al., PDGFRA gain in low-grade diffuse gliomas, Journal of neuropathology and experimental neurology, vol.72, pp.61-66, 2006.

, Bulletin du cancer, vol.93, pp.1139-1143

E. C. Moyal, A. Laprie, M. Delannes, M. Poublanc, I. Catalaa et al., Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme, International journal of radiation oncology, vol.68, pp.1396-1401, 2007.

D. Mukherjee, J. M. Sarmiento, D. Ly, M. A. Nuno, and C. G. Patil, Everolimus for astrocytomas in tuberous sclerosis, Lancet, vol.381, pp.1274-1275, 2013.

M. Murakami, International journal of vascular medicine 2012:293641. N Nagano O, Saya H (2004) Mechanism and biological significance of CD44 cleavage, Cancer science, vol.95, pp.930-935, 2012.

S. Nagpal, G. Harsh, and L. Recht, Bevacizumab improves quality of life in patients with recurrent glioblastoma, p.602812, 2011.

T. Nakayama, T. Hirose, K. Totsune, N. Mori, Y. Maruyama et al., Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure, Peptides, vol.29, pp.801-808, 2008.

A. Narayana, S. D. Kunnakkat, P. Medabalmi, J. Golfinos, E. Parker et al., Change in pattern of relapse after antiangiogenic therapy in high-grade glioma, International journal of radiation oncology, vol.82, pp.77-82, 2012.

E. S. Newlands, M. F. Stevens, S. R. Wedge, R. T. Wheelhouse, and C. Brock, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer treatment reviews, vol.23, pp.35-61, 1997.

L. L. Ng, I. Loke, R. J. O'brien, I. B. Squire, and J. E. Davies, Plasma urotensin in human systolic heart failure, Circulation, vol.106, pp.2877-2880, 2002.

P. L. Nghiemphu, A. Lai, R. M. Green, D. A. Reardon, and T. Cloughesy, A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas, Journal of neuro-oncology, vol.110, pp.245-250, 2012.

P. L. Nghiemphu, P. Y. Wen, K. R. Lamborn, J. Drappatz, H. I. Robins et al., North American Brain Tumor C (2011) A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma, International journal of radiation oncology, vol.81, pp.1422-1427

T. T. Nguyen, M. Letourneau, D. Chatenet, and A. Fournier, Presence of urotensin-II receptors at the cell nucleus: specific tissue distribution and hypoxia-induced modulation, The international journal of biochemistry & cell biology, vol.44, pp.639-647, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-00817600

N. Nitescu, E. Grimberg, and G. Guron, Urotensin-II receptor antagonism does not improve renal haemodynamics or function in rats with endotoxin-induced acute kidney injury, Clinical and experimental pharmacology & physiology, vol.37, pp.1170-1175, 2010.

S. Nobata, J. A. Donald, R. J. Balment, and Y. Takei, Potent cardiovascular effects of homologous urotensin II (UII)-related peptide and UII in unanesthetized eels after peripheral and central injections, American journal of physiology Regulatory, integrative and comparative physiology, vol.300, pp.437-446, 2011.

M. Noble and J. Dietrich, The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity, Trends in neurosciences, vol.27, pp.148-154, 2004.

G. Noel, R. Schott, S. Froelich, M. P. Gaub, P. Boyer et al., Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas, International journal of radiation oncology, vol.82, pp.749-755, 2012.

T. Nomura, T. Inamura, and K. L. Black, Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors, Brain research, vol.659, pp.62-66, 1994.

A. D. Norden, J. Drappatz, and P. Y. Wen, Novel anti-angiogenic therapies for malignant gliomas, The Lancet Neurology, vol.7, pp.1152-1160, 2008.

H. P. Nothacker, Z. Wang, A. M. Mcneill, Y. Saito, S. Merten et al., Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction, Nature cell biology, vol.1, pp.383-385, 1999.

E. Nouguerede, C. Berenguer, S. Garcia, B. Bennani, C. Delfino et al., Expression of adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenograft growth in vivo, Cancer medicine, vol.2, pp.196-207, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01708110

H. Ohgaki and P. Kleihues, Epidemiology and etiology of gliomas, Acta neuropathologica, vol.109, pp.93-108, 2005.

H. Ohgaki and P. Kleihues, Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas, Journal of neuropathology and experimental neurology, vol.64, pp.479-489, 2005.

H. Ohgaki and P. Kleihues, Genetic alterations and signaling pathways in the evolution of gliomas, Cancer science, vol.100, pp.2235-2241, 2009.

E. Oikonomou, M. Buchfelder, and E. F. Adams, Cholecystokinin (CCK) and CCK receptor expression by human gliomas: Evidence for an autocrine/paracrine stimulatory loop, Neuropeptides, vol.42, pp.255-265, 2008.

H. Okada, T. Tsuzuki, H. Shindoh, A. Nishigaki, K. Yasuda et al., Regulation of decidualization and angiogenesis in the human endometrium: mini review, The journal of obstetrics and gynaecology research, vol.40, pp.1180-1187, 2014.

I. Okamoto, Y. Kawano, H. Tsuiki, J. Sasaki, M. Nakao et al., CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration, Oncogene, vol.18, pp.1435-1446, 1999.

R. J. Plunkett, A. Lis, T. A. Barone, M. D. Fronckowiak, and S. J. Greenberg, Hormonal effects on glioblastoma multiforme in the nude rat model, Journal of neurosurgery, vol.90, pp.1072-1077, 1999.

C. Porras-gonzalez, J. Urena, J. J. Egea-guerrero, E. Gordillo-escobar, F. Murillo-cabezas et al., Contractile responses to rat urotensin II in resting and depolarized basilar arteries, Journal of physiology and biochemistry, vol.70, pp.193-199, 2014.

E. Pozsgai, A. V. Schally, G. Halmos, F. Rick, and S. Bellyei, The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma, Hormone and metabolic research, vol.42, pp.781-786, 2010.

S. Previtali, A. Quattrini, R. Nemni, G. Truci, A. Ducati et al., Alpha6 beta4 and alpha6 beta1 integrins in astrocytomas and other CNS tumors, Journal of neuropathology and experimental neurology, vol.55, pp.456-465, 1996.

A. Price, Q. Shi, D. Morris, M. E. Wilcox, P. M. Brasher et al., Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340, Clinical cancer research, vol.5, pp.845-854, 1999.

H. C. Prosser, M. E. Forster, A. M. Richards, and C. J. Pemberton, Urotensin II and urotensin IIrelated peptide (URP) in cardiac ischemia-reperfusion injury, Peptides, vol.29, pp.770-777, 2008.

H. C. Prosser, J. Leprince, H. Vaudry, A. M. Richards, M. E. Forster et al., Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts, Peptides, vol.27, pp.3261-3268, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01973954

C. D. Proulx, B. J. Holleran, A. A. Boucard, E. Escher, G. Guillemette et al., Mutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptor, Molecular pharmacology, vol.74, pp.552-561, 2008.

D. Provost, A. Cantagrel, P. Lebailly, A. Jaffre, V. Loyant et al., Brain tumours and exposure to pesticides: a case-control study in southwestern France, Occupational and environmental medicine, vol.64, pp.509-514, 2007.

J. Qi, J. Du, X. Tang, J. Li, B. Wei et al., The upregulation of endothelial nitric oxide synthase and urotensin-II is associated with pulmonary hypertension and vascular diseases in rats produced by aortocaval shunting, Heart and vessels, vol.19, pp.81-88, 2004.

J. S. Qi, R. Schulingkamp, T. J. Parry, R. Colburn, D. Stone et al., Urotensin-II induces ear flushing in rats, British journal of pharmacology, vol.150, pp.415-423, 2007.

S. J. Qualman, J. Bowen, and S. H. Erdman, Molecular basis of the brain tumor-polyposis (Turcot) syndrome, Pediatric and developmental pathology, vol.6, pp.574-576, 2003.

F. B. Quan, M. Bougerol, F. Rigour, N. B. Kenigfest, and H. Tostivint, Characterization of the true ortholog of the urotensin II-related peptide (URP) gene in teleosts, General and comparative endocrinology, vol.177, pp.205-212, 2012.

K. Radhakrishnan, B. Mokri, J. E. Parisi, W. M. O'fallon, J. Sunku et al., The trends in incidence of primary brain tumors in the population of, Annals of neurology, vol.37, pp.67-73, 1995.

J. J. Raizer, L. E. Abrey, A. B. Lassman, S. M. Chang, K. R. Lamborn et al., North American Brain Tumor C (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy, Neuro-oncology, vol.12, pp.95-103

J. J. Raizer, L. E. Abrey, A. B. Lassman, S. M. Chang, K. R. Lamborn et al., North American Brain Tumor C (2010) A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas, Neuro-oncology, vol.12, pp.87-94

P. Rajaraman, S. S. Wang, N. Rothman, M. M. Brown, P. M. Black et al., Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults, Cancer Research, vol.16, pp.1655-1661, 2007.

E. Rakowski, G. S. Hassan, D. Dhanak, E. H. Ohlstein, S. A. Douglas et al., A role for urotensin II in restenosis following balloon angioplasty: use of a selective UT receptor blocker, Journal of molecular and cellular cardiology, vol.39, pp.785-791, 2005.

P. Ravani, G. Tripepi, P. Pecchini, F. Mallamaci, F. Malberti et al., Urotensin II is an inverse predictor of death and fatal cardiovascular events in chronic kidney disease, Kidney international, vol.73, pp.95-101, 2008.

S. M. Raza, G. N. Fuller, C. H. Rhee, S. Huang, K. Hess et al., Identification of necrosis-associated genes in glioblastoma by cDNA microarray analysis, Clinical cancer research, vol.10, pp.212-221, 2004.

S. M. Raza, F. F. Lang, B. B. Aggarwal, G. N. Fuller, D. M. Wildrick et al., Necrosis and glioblastoma: a friend or a foe? A review and a hypothesis, Neurosurgery, vol.51, pp.2-12, 2002.

D. A. Reardon, G. Dresemann, S. Taillibert, M. Campone, M. Van-den-bent et al., Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma, British journal of cancer, vol.101, pp.1995-2004, 2009.

D. A. Reardon, M. J. Egorin, A. Desjardins, J. J. Vredenburgh, J. H. Beumer et al., Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma, Cancer, vol.115, pp.2188-2198, 2009.

D. A. Reardon, K. L. Fink, T. Mikkelsen, T. F. Cloughesy, A. O'neill et al., Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, Journal of clinical oncology, vol.26, pp.5610-5617, 2008.

D. A. Reardon, M. D. Groves, P. Y. Wen, L. Nabors, T. Mikkelsen et al., A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma, Clinical cancer research, vol.19, pp.900-908, 2013.

D. A. Reardon, J. E. Herndon, K. Peters, A. Desjardins, A. Coan et al., Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients, Journal of neuro-oncology, vol.107, pp.213-221, 2012.

D. A. Reardon, J. A. Quinn, J. J. Vredenburgh, S. Gururangan, A. H. Friedman et al., Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma, Clinical cancer research, vol.12, pp.860-868, 2006.

D. A. Reardon, J. J. Vredenburgh, A. Coan, A. Desjardins, K. B. Peters et al., Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma, Journal of neuro-oncology, vol.105, pp.621-627, 2011.

A. Reaux-le-goazigo, J. Van-steenwinckel, W. Rostene, M. Parsadaniantz, and S. , Current status of chemokines in the adult CNS, Progress in neurobiology, vol.104, pp.67-92, 2013.

M. H. Repacholi, Health risks from the use of mobile phones, Toxicology letters, vol.120, pp.323-331, 2001.

L. Ricci-vitiani, R. Pallini, M. Biffoni, M. Todaro, G. Invernici et al., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature, vol.468, pp.824-828, 2010.

J. N. Rich, D. A. Reardon, T. Peery, J. M. Dowell, J. A. Quinn et al., Phase II trial of gefitinib in recurrent glioblastoma, Journal of clinical oncology, vol.22, pp.133-142, 2004.

A. M. Richards, M. G. Nicholls, J. G. Lainchbury, S. Fisher, and T. G. Yandle, Plasma urotensin II in heart failure, Lancet, vol.360, pp.545-546, 2002.

M. J. Riemenschneider, J. W. Jeuken, P. Wesseling, and G. Reifenberger, Molecular diagnostics of gliomas: state of the art, Acta neuropathologica, vol.120, pp.567-584, 2010.

R. J. Rivas, R. S. Nishioka, and H. A. Bern, In vitro effects of somatostatin and urotensin II on prolactin and growth hormone secretion in tilapia, Oreochromis mossambicus. General and comparative endocrinology, vol.63, pp.245-251, 1986.

E. Rivera, O. Arrieta, P. Guevara, A. Duarte-rojo, and J. Sotelo, AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma, British journal of cancer, vol.85, pp.1396-1399, 2001.

R. Irizarry, L. Hambardzumyan, D. Nakano, I. Gladson, C. L. Ahluwalia et al., Therapeutic targeting of VEGF in the treatment of glioblastoma, Expert opinion on therapeutic targets, vol.16, pp.973-984, 2012.

F. J. Rodriguez, B. A. Orr, K. L. Ligon, and C. G. Eberhart, Neoplastic cells are a rare component in human glioblastoma microvasculature, Oncotarget, vol.3, pp.98-106, 2012.

M. Roger, A. Clavreul, M. C. Venier-julienne, C. Passirani, C. Montero-menei et al., The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy, Biomaterials, vol.32, pp.2106-2116, 2011.

M. Roger, A. Clavreul, M. C. Venier-julienne, C. Passirani, L. Sindji et al., Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors, Biomaterials, vol.31, pp.8393-8401, 2010.

K. Rolle, S. Nowak, E. Wyszko, M. Nowak, R. Zukiel et al., Promising human brain tumors therapy with interference RNA intervention (iRNAi), Cancer biology & therapy, vol.9, pp.396-406, 2010.

E. V. Romanova, K. Sasaki, V. Alexeeva, F. S. Vilim, J. Jing et al., Urotensin II in invertebrates: from structure to function in Aplysia californica, PloS one, vol.7, p.48764, 2012.

R. E. Modan, B. Boice, J. D. , J. Alfandary, E. Stovall et al., Tumors of the brain and nervous system after radiotherapy in childhood, The New England journal of medicine, vol.319, pp.1033-1039, 1988.

Y. Rong, D. L. Durden, E. G. Van-meir, and D. J. Brat, Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis, Journal of neuropathology and experimental neurology, vol.65, pp.529-539, 2006.

H. K. Rooprai, G. J. Rucklidge, C. Panou, and G. J. Pilkington, The effects of exogenous growth factors on matrix metalloproteinase secretion by human brain tumour cells, British journal of cancer, vol.82, pp.52-55, 2000.

B. Ross, K. Mckendy, and A. Giaid, Role of urotensin II in health and disease, American journal of physiology Regulatory, integrative and comparative physiology, vol.298, pp.1156-1172, 2010.

W. J. Rossowski, B. L. Cheng, J. E. Taylor, R. Datta, and D. H. Coy, Human urotensin II-induced aorta ring contractions are mediated by protein kinase C, tyrosine kinases and Rhokinase: inhibition by somatostatin receptor antagonists, European journal of pharmacology, vol.438, pp.159-170, 2002.

P. Rousseau, J. L. Habrand, D. Sarrazin, C. Kalifa, M. J. Terrier-lacombe et al., Treatment of intracranial ependymomas of children: review of a 15-year experience, International journal of radiation oncology, vol.28, pp.381-386, 1994.

R. J. Ruch, The role of gap junctional intercellular communication in neoplasia, Annals of clinical and laboratory science, vol.24, pp.216-231, 1994.

A. M. Ruder, M. A. Waters, M. A. Butler, T. Carreon, G. M. Calvert et al., Brain Cancer Collaborative Study G (2004) Gliomas and farm pesticide exposure in men: the upper midwest health study, Archives of environmental health, vol.59, pp.650-657

F. D. Russell, D. Meyers, A. J. Galbraith, N. Bett, I. Toth et al., Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure, American journal of physiology Heart and circulatory physiology, vol.285, pp.1576-1581, 2003.

F. D. Russell and P. Molenaar, Investigation of signaling pathways that mediate the inotropic effect of urotensin-II in human heart, Cardiovascular research, vol.63, pp.673-681, 2004.

F. D. Russell, P. Molenaar, O. 'brien, and D. M. , Cardiostimulant effects of urotensin-II in human heart in vitro, British journal of pharmacology, vol.132, pp.5-9, 2001.

N. Sadamori, S. Shibata, M. Mine, H. Miyazaki, H. Miyake et al., Incidence of intracranial meningiomas in Nagasaki atomic-bomb survivors, International journal of cancer, vol.67, pp.318-322, 1996.

O. Saetrum-opgaard, H. Nothacker, F. J. Ehlert, and D. N. Krause, Human urotensin II mediates vasoconstriction via an increase in inositol phosphates, European journal of pharmacology, vol.406, pp.265-271, 2000.

M. E. Saez, T. Smani, R. Ramirez-lorca, I. Diaz, M. Serrano-rios et al., Association analysis of urotensin II gene (UTS2) and flanking regions with biochemical parameters related to insulin resistance, PloS one, vol.6, p.19327, 2011.

P. Saharinen, L. Eklund, K. Pulkki, P. Bono, and K. Alitalo, VEGF and angiopoietin signaling in tumor angiogenesis and metastasis, Trends in molecular medicine, vol.17, pp.347-362, 2011.

X. Sainsily, J. Cabana, B. J. Holleran, E. Escher, P. Lavigne et al., Identification of transmembrane domain 1 & 2 residues that contribute to the formation of the ligandbinding pocket of the urotensin-II receptor, Biochemical pharmacology, vol.92, pp.280-288, 2014.

M. Salcman, Glioblastoma multiforme, The American journal of the medical sciences, vol.279, pp.84-94, 1980.

M. Salcman, Survival in glioblastoma: historical perspective, Neurosurgery, vol.7, pp.435-439, 1980.

B. Salhia, F. Rutten, M. Nakada, C. Beaudry, M. Berens et al., Inhibition of Rho-kinase affects astrocytoma morphology, motility, and invasion through activation of Rac1, Cancer research, vol.65, pp.8792-8800, 2005.

M. Salvati, E. Caroli, G. Rocchi, A. Frati, C. Brogna et al., Post-traumatic glioma. Report of four cases and review of the literature, Tumori, vol.90, pp.416-419, 2004.

O. Salvucci and G. Tosato, Essential roles of EphB receptors and EphrinB ligands in endothelial cell function and angiogenesis, Advances in cancer research, vol.114, pp.21-57, 2012.

V. Sauzeau, L. Mellionnec, E. Bertoglio, J. Scalbert, E. Pacaud et al., Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase, Circulation research, vol.88, pp.1102-1104, 2001.

R. Scatena, Prinomastat, a hydroxamate-based matrix metalloproteinase inhibitor. A novel pharmacological approach for tissue remodelling-related diseases, Expert opinion on investigational drugs, vol.9, pp.2159-2165, 2000.

A. Schulte, K. Liffers, A. Kathagen, S. Riethdorf, S. Zapf et al., Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110delta, Neuro-oncology, vol.15, pp.1289-1301, 2013.

B. J. Scott, E. C. Quant, M. B. Mcnamara, P. A. Ryg, T. T. Batchelor et al., Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors, Neuro-oncology, vol.12, pp.603-607, 2010.

J. P. Segain, M. Rolli-derkinderen, N. Gervois, R. De-la-bletiere, D. Loirand et al., Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes, Journal of immunology, vol.179, pp.901-909, 2007.

M. Segarra, H. Ohnuki, D. Maric, O. Salvucci, X. Hou et al., Semaphorin 6A regulates angiogenesis by modulating VEGF signaling, Blood, vol.120, pp.4104-4115, 2012.

G. L. Semenza, Targeting HIF-1 for cancer therapy, Nature reviews Cancer, vol.3, pp.721-732, 2003.

G. Shao, Y. Zhou, F. Wang, and S. Liu, Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin alphavbeta3, Molecular imaging, vol.12, pp.39-48, 2013.

A. Sharma, J. Walters, Y. Gozes, M. Fridkin, D. Brenneman et al., A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells, Journal of molecular neuroscience, vol.17, pp.331-339, 2001.

A. Shenouda, S. A. Douglas, E. H. Ohlstein, and A. Giaid, Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma, The journal of histochemistry and cytochemistry, vol.50, pp.885-889, 2002.

L. Shi, W. Ding, D. Li, Z. Wang, H. Jiang et al., Proliferation and antiapoptotic effects of human urotensin II on human endothelial cells, Atherosclerosis, vol.188, pp.260-264, 2006.

X. D. Shi, Z. L. Li, H. C. Wu, Y. H. Lu, T. H. Wang et al., , 2005.

, Chinese journal of cardiovascular diseases, vol.33, pp.836-839

X. D. Shi, Z. L. Li, H. C. Wu, T. H. Wang, Q. Fu et al., Mechanism of urotensin II-stimulated adrenomedullin secretion in human vascular endothelial cells, Academic journal of the first medical college of PLA, vol.25, pp.791-793, 2005.

Y. Shi, Y. X. Cao, N. Lu, T. Yao, and Y. C. Zhu, Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats, Peptides, vol.29, pp.783-794, 2008.

T. Shintani, N. Hayakawa, M. Hoshi, M. Sumida, K. Kurisu et al., High incidence of meningioma among Hiroshima atomic bomb survivors, Journal of radiation research, vol.40, pp.49-57, 1999.

Y. Shiraishi, T. Watanabe, T. Suguro, M. Nagashima, R. Kato et al., Chronic urotensin II infusion enhances macrophage foam cell formation and atherosclerosis in apolipoprotein E-knockout mice, Journal of hypertension, vol.26, pp.1955-1965, 2008.

K. G. Shyu, B. W. Wang, W. J. Chen, P. Kuan, and C. M. Lin, Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast, European journal of clinical investigation, vol.42, pp.17-26, 2012.

A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy, European journal of cancer, vol.42, pp.717-727, 2006.

P. N. Sidharta, K. Rave, L. Heinemann, E. Chiossi, S. Krahenbuhl et al., Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus, British journal of clinical pharmacology, vol.68, pp.502-510, 2009.

P. N. Sidharta, F. D. Wagner, H. Bohnemeier, A. Jungnik, A. Halabi et al., Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients, Clinical pharmacology and therapeutics, vol.80, pp.246-256, 2006.

R. A. Silvestre, E. M. Egido, R. Hernandez, J. Leprince, D. Chatenet et al., Urotensin-II is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas, European journal of endocrinology, vol.151, pp.803-809, 2004.
URL : https://hal.archives-ouvertes.fr/hal-01974193

R. A. Silvestre, E. M. Egido, R. Hernandez, and J. Marco, Characterization of the insulinostatic effect of urotensin II: a study in the perfused rat pancreas, Regulatory peptides, vol.153, pp.37-42, 2009.

R. A. Silvestre, J. Rodriguez-gallardo, E. M. Egido, and J. Marco, Inhibition of insulin release by urotensin II--a study on the perfused rat pancreas, Hormone and metabolic research, vol.33, pp.379-381, 2001.

M. T. Solomon, J. C. Selva, J. Figueredo, J. Vaquer, C. Toledo et al., Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial, BMC cancer, vol.13, p.299, 2013.

H. Song, Y. Li, J. Lee, A. L. Schwartz, and G. Bu, Low-density lipoprotein receptor-related protein 1 promotes cancer cell migration and invasion by inducing the expression of matrix metalloproteinases 2 and 9, Cancer research, vol.69, pp.879-886, 2009.

N. Song, W. Ding, S. Chu, J. Zhao, X. Dong et al., Urotensin II stimulates vascular endothelial growth factor secretion from adventitial fibroblasts in synergy with angiotensin II, Circulation journal, vol.76, pp.1267-1273, 2012.

W. Song, A. E. Abdel-razik, W. Lu, Z. Ao, D. G. Johns et al., Urotensin II and renal function in the rat, Kidney international, vol.69, pp.1360-1368, 2006.

W. Song, J. Mcdonald, V. Camarda, G. Calo, R. Guerrini et al., Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity, Naunyn-Schmiedeberg's archives of pharmacology, vol.373, pp.148-157, 2006.

H. Soni and A. Adebiyi, Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs, The Journal of endocrinology, vol.217, pp.317-326, 2013.

L. Soroceanu, T. J. Manning, and H. Sontheimer, Reduced expression of connexin-43 and functional gap junction coupling in human gliomas, Glia, vol.33, pp.107-117, 2001.

R. Spinazzi, G. Albertin, B. Nico, D. Guidolin, D. Liddo et al., Urotensin-II and its receptor (UT-R) are expressed in rat brain endothelial cells, and urotensin-II via UT-R stimulates angiogenesis in vivo and in vitro, International journal of molecular medicine, vol.18, pp.1107-1112, 2006.

M. F. Stevens, J. A. Hickman, S. P. Langdon, D. Chubb, L. Vickers et al., Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo, 1987.

M. , 39831), a novel drug with potential as an alternative to dacarbazine, Cancer research, vol.47, pp.5846-5852

L. A. Stewart, Chemotherapy in adult high-grade glioma: a systematic review and metaanalysis of individual patient data from 12 randomised trials, Lancet, vol.359, pp.1011-1018, 2002.

A. Stirrat, M. Gallagher, S. A. Douglas, E. H. Ohlstein, C. Berry et al., Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries, American journal of physiology Heart and circulatory physiology, vol.280, pp.925-928, 2001.

S. I. Stiver, Angiogenesis and its role in the behavior of astrocytic brain tumors, Frontiers in bioscience, vol.9, pp.3105-3123, 2004.

R. Stupp, M. E. Hegi, B. Neyns, R. Goldbrunner, U. Schlegel et al., Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma, Journal of clinical oncology, vol.28, pp.2712-2718, 2010.

R. Stupp, W. P. Mason, M. J. Van-den-bent, M. Weller, B. Fisher et al., European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, The New England journal of medicine, vol.352, pp.987-996

Y. M. Sue, C. H. Chen, Y. H. Hsu, C. C. Hou, C. Y. Cheng et al., Urotensin II induces transactivation of the epidermal growth factor receptor via transient oxidation of SHP-2 in the rat renal tubular cell line NRK-52E, Growth factors, vol.27, pp.155-162, 2009.

T. Ulas, I. Tursun, M. S. Dal, M. E. Demir, and Z. Kaya, A forgotten vasoconstrictive peptide in the pathogenesis of contrast induced nephropathy: urotensin-II, International journal of cardiology, vol.166, p.258, 2013.

I. Ulasov, B. Thaci, P. Sarvaiya, R. Yi, D. Guo et al., Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas, Cancer medicine, vol.2, pp.457-467, 2013.

S. Utsuki, Y. Sato, H. Oka, B. Tsuchiya, S. Suzuki et al., Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas, Journal of neuro-oncology, vol.57, pp.187-192, 2002.

A. V-vartanian, S. K. Singh, S. Agnihotri, S. Jalali, K. Burrell et al., GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity, Neuro-oncology, vol.16, pp.1167-1175, 2014.

P. Vaupel, F. Kallinowski, and P. Okunieff, Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review, Cancer research, vol.49, pp.6449-6465, 1989.

A. L. Vavere and R. Rossin, Molecular imaging of cancer with radiolabeled peptides and PET, Anti-cancer agents in medicinal chemistry, vol.12, pp.462-475, 2012.

D. Verdegem, S. Moens, P. Stapor, and P. Carmeliet, Endothelial cell metabolism: parallels and divergences with cancer cell metabolism, Cancer & metabolism, vol.2, p.19, 2014.

R. Vergura, V. Camarda, A. Rizzi, M. Spagnol, R. Guerrini et al., Urotensin II stimulates plasma extravasation in mice via UT receptor activation, Naunyn-Schmiedeberg's archives of pharmacology, vol.370, pp.347-352, 2004.

R. G. Verhaak, K. A. Hoadley, E. Purdom, V. Wang, Y. Qi et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Genome Atlas Research N, vol.17, pp.98-110, 2010.

R. Virchow, Cellular pathology. As based upon physiological and pathological histology. Lecture XVI--Atheromatous affection of arteries. 1858, Nutrition reviews, vol.47, pp.23-25, 1989.

L. Vogt, C. Chiurchiu, H. Chadha-boreham, P. Danaietash, J. Dingemanse et al., Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathy, Hypertension, vol.55, pp.1206-1209, 2010.

H. Wang, K. Dong, X. Xue, P. Feng, and X. Wang, Elevated expression of urotensin II and its receptor in diethylnitrosamine-mediated precancerous lesions in rat liver, Peptides, vol.32, pp.382-387, 2011.

H. Wang, H. Wang, W. Shen, H. Huang, L. Hu et al., Insulin-like growth factor binding protein 2 enhances glioblastoma invasion by activating invasion-enhancing genes, Cancer research, vol.63, pp.4315-4321, 2003.

H. X. Wang, X. J. Zeng, Y. Liu, J. Wang, L. Q. Lu et al., Elevated expression of urotensin II and its receptor in skeletal muscle of diabetic mouse, Regulatory peptides, vol.154, pp.85-90, 2009.

Y. Wang, S. Guan, G. Zhao, P. Shi, and J. Wang, Expressions of aquaporin-4, matrix metalloproteinase-2 and matrix metallo-proteinase-14 in peritumor edematous zone of glioma and clinical implications, Journal of the chinese medical association, vol.94, pp.2290-2292, 2014.

Y. Wang, M. Nakayama, M. E. Pitulescu, T. S. Schmidt, M. L. Bochenek et al., Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis, Nature, vol.465, pp.483-486, 2010.

Y. X. Wang, Y. J. Ding, Y. Z. Zhu, Y. Shi, T. Yao et al., Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction, American journal of physiology heart and circulatory physiology, vol.292, pp.348-359, 2007.

A. Watanabe, T. Mabuchi, E. Satoh, K. Furuya, L. Zhang et al., Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression, Journal of neuro-oncology, vol.77, pp.25-32, 2006.

T. Watanabe, R. Pakala, T. Katagiri, and C. R. Benedict, Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation, Journal of hypertension, vol.19, pp.2191-2196, 2001.

T. Watanabe, T. Suguro, T. Kanome, Y. Sakamoto, S. Kodate et al., Human urotensin II accelerates foam cell formation in human monocyte-derived macrophages, Hypertension, vol.46, pp.738-744, 2005.

A. M. Watson, G. W. Lambert, K. J. Smith, and C. N. May, Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions, Hypertension, vol.42, pp.373-379, 2003.

D. Waugh, J. Youson, S. D. Mims, S. Sower, and J. M. Conlon, Urotensin II from the river lamprey (Lampetra fluviatilis), the sea lamprey (Petromyzon marinus), and the paddlefish (Polyodon spathula), General and comparative endocrinology, vol.99, pp.323-332, 1995.

J. Welti, S. Loges, S. Dimmeler, and P. Carmeliet, Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer, The Journal of clinical investigation, vol.123, pp.3190-3200, 2013.

P. Y. Wen and S. Kesari, Malignant gliomas in adults, The New England journal of medicine, vol.359, pp.492-507, 2008.

A. Werner, B. Modan, and D. Davidoff, Doses to brain, skull and thyroid, following x-ray therapy for Tinea capitis, Physics in medicine and biology, vol.13, pp.247-258, 1968.

W. Wick, M. Platten, and M. Weller, Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta, Journal of neuro-oncology, vol.53, pp.177-185, 2001.

J. K. Wiencke, K. Aldape, A. Mcmillan, J. Wiemels, M. Moghadassi et al., Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNAmethyltransferase, biomarkers & prevention, vol.14, pp.1774-1783, 2005.

J. L. Wilding and W. F. Bodmer, Cancer cell lines for drug discovery and development, Cancer research, vol.74, pp.2377-2384, 2014.

E. C. Wooten, D. Fults, R. Duggirala, K. Williams, A. P. Kyritsis et al., A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multiforme with implications for tumor evolution, Neuro-oncology, vol.1, pp.169-176, 1999.

J. L. Wright and R. E. Merchant, Effects of an intratumoral injection of human recombinant tumor necrosis factor-alpha on cerebrovascular permeability and leukocytic infiltration in a rat glioma model, Acta neuropathologica, vol.93, pp.78-86, 1997.

S. Xu, H. Jiang, B. Wu, J. Yang, and S. Chen, Urotensin II induces migration of endothelial progenitor cells via activation of the RhoA/Rho kinase pathway, The Tohoku journal of experimental medicine, vol.219, pp.283-288, 2009.

S. Xu, H. Wen, and H. Jiang, Urotensin II promotes the proliferation of endothelial progenitor cells through p38 and p44/42 MAPK activation, Molecular medicine reports, vol.6, pp.197-200, 2012.

H. Yan, D. W. Parsons, J. G. Mclendon, R. Rasheed, B. A. Yuan et al., IDH1 and IDH2 mutations in gliomas, vol.360, pp.765-773, 2009.

L. Yang, C. Lin, L. Wang, H. Guo, and X. Wang, Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications, Experimental cell research, vol.318, pp.2417-2426, 2012.

M. Yang, S. Adla, M. K. Temburni, V. P. Patel, E. L. Lagow et al., Stimulation of glioma cell motility by expression, proteolysis, and release of the L1 neural cell recognition molecule, Cancer cell international, vol.9, p.27, 2009.

Y. Yang, M. Sun, L. Wang, and B. Jiao, HIFs, angiogenesis, and cancer, Journal of cellular biochemistry, vol.114, pp.967-974, 2013.

K. Yano, J. W. Hicks, H. Vaudry, and J. M. Conlon, Cardiovascular actions of frog urotensin II in the frog, Rana catesbeiana, General and comparative endocrinology, vol.97, pp.103-110, 1995.

K. Yi, M. Yu, L. Wu, and X. Tan, Effects of urotensin II on functional activity of late endothelial progenitor cells, Peptides, vol.33, pp.87-91, 2012.

Y. Yongjun, H. Shuyun, C. Lei, C. Xiangrong, Y. Zhilin et al., Atorvastatin suppresses glioma invasion and migration by reducing microglial MT1-MMP expression, Journal of neuroimmunology, vol.260, pp.1-8, 2013.

W. K. You and D. M. Mcdonald, The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis, BMB reports, vol.41, pp.833-839, 2008.

W. Y. Yue and Z. P. Chen, Does vasculogenic mimicry exist in astrocytoma?, The journal of histochemistry and cytochemistry, vol.53, pp.997-1002, 2005.

C. R. Yulis and K. Lederis, Extraurophyseal distribution of urotensin II immunoreactive neuronal perikarya and their processes, Proceedings of the National Academy of Sciences of the United States of America, vol.83, pp.7079-7083, 1986.

W. K. Yung, R. E. Albright, J. Olson, R. Fredericks, K. Fink et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, British journal of cancer, vol.83, pp.588-593, 2000.

P. D. Yurchenco, Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harbor perspectives in biology 3, 2011.

S. Yust-katz, D. Liu, Y. Yuan, V. Liu, S. Kang et al., Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma, Cancer, vol.119, pp.2747-2753, 2013.

D. Zagzag, Y. Lukyanov, L. Lan, M. A. Ali, M. Esencay et al., Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion, Laboratory investigation, vol.86, pp.1221-1232, 2006.

D. Zagzag, H. Zhong, J. M. Scalzitti, E. Laughner, J. W. Simons et al., Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression, Cancer, vol.88, pp.2606-2618, 2000.

Z. P. Zeng, G. Q. Liu, H. Z. Li, X. R. Fan, D. M. Liu et al., The effects of urotensin-II on proliferation of pheochromocytoma cells and mRNA expression of urotensin-II and its receptor in pheochromocytoma tissues, Annals of the New York Academy of Sciences, vol.1073, pp.284-289, 2006.

B. R. Zetter, Angiogenesis and tumor metastasis, Annual review of medicine, vol.49, pp.407-424, 1998.

A. Y. Zhang, Y. F. Chen, D. X. Zhang, F. X. Yi, J. Qi et al., Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney, American journal of physiology. Renal physiology, vol.285, pp.792-798, 2003.

J. Zhang, J. Yang, and Y. Liu, Role of Bcl-xL induction in HGF-mediated renal epithelial cell survival after oxidant stress, International journal of clinical and experimental pathology, vol.1, pp.242-253, 2008.

W. X. Zhang, Y. F. Liang, X. M. Wang, Y. Nie, L. Chong et al., Urotensin upregulates transforming growth factor-beta1 expression of asthma airway through ERK-dependent pathway, Molecular and cellular biochemistry, vol.364, pp.291-298, 2012.

Y. Zhang, S. Bao, Z. Kuang, Y. Ma, Y. Hu et al., Urotensin II promotes monocyte chemoattractant protein-1 expression in aortic adventitial fibroblasts of rat, Chinese medical journal, vol.127, pp.1907-1912, 2014.

Y. Zhang, J. Li, J. Cao, J. Chen, J. Yang et al., Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium, Heart and vessels, vol.16, pp.64-68, 2002.

Y. G. Zhang, Z. J. Kuang, Y. Y. Mao, R. H. Wei, S. L. Bao et al., Osteopontin is involved in urotensin II-induced migration of rat aortic adventitial fibroblasts, Peptides, vol.32, pp.2452-2458, 2011.

Y. G. Zhang, J. Li, Y. G. Li, and R. H. Wei, Urotensin II induces phenotypic differentiation, migration, and collagen synthesis of adventitial fibroblasts from rat aorta, Journal of hypertension, vol.26, pp.1119-1126, 2008.

Y. G. Zhang, Y. G. Li, B. G. Liu, R. H. Wei, D. M. Wang et al., Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol, Acta pharmacologica Sinica, vol.28, pp.36-43, 2007.

D. Zhao, D. Alizadeh, L. Zhang, W. Liu, O. Farrukh et al., Carbon nanotubes enhance CpG uptake and potentiate antiglioma immunity, Clinical cancer research, vol.17, pp.771-782, 2011.

J. Zhao, L. D. Xie, C. J. Song, X. X. Mao, H. R. Yu et al., Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-beta expression in rats, Experimental and therapeutic medicine, vol.7, pp.1647-1652, 2014.

Y. Zhao, J. Dong, Q. Huang, M. Lou, A. Wang et al., Endothelial cell transdifferentiation of human glioma stem progenitor cells in vitro, Brain research bulletin, vol.82, pp.308-312, 2010.

C. H. Zhou, Y. Y. Wan, X. H. Chu, Z. Song, S. H. Xing et al., Urotensin II contributes to the formation of lung adenocarcinoma inflammatory microenvironment through the NF-kappaB pathway in tumor-bearing nude mice, Oncology letters, vol.4, pp.1259-1263, 2012.

H. Y. Zhou, Y. L. Pon, and A. S. Wong, HGF/MET signaling in ovarian cancer, Current molecular medicine, vol.8, pp.469-480, 2008.

Y. Z. Zhu, Z. J. Wang, Y. C. Zhu, L. Zhang, R. M. Oakley et al., Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile, American journal of physiology Heart and circulatory physiology, vol.286, pp.830-836, 2004.

P. Ziltener, C. Mueller, B. Haenig, M. W. Scherz, and O. Nayler, Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines, Journal of receptor and signal transduction research, vol.22, pp.155-168, 2002.

, Neuroprotective effects of PACAP against ethanol-induced toxicity in the developing rat cerebellum

B. Botia, V. Jolivel, D. Burel, L. Joncour, V. Roy et al., Neurotox Res, vol.19, issue.3, pp.423-457, 2011.

Y. Joyard, L. Joncour, V. Castel, H. Diouf, C. B. Bischoff et al., Bioorg Med Chem Lett, vol.23, issue.13, pp.3704-3712, 2013.

, Synthesis, biological evaluation, and in vivo imaging of the first camptothecinfluorescein conjugate

A. Chevalier, M. Dubois, L. Joncour, V. Dautrey, S. Lecointre et al., Bioconjug Chem, vol.24, issue.7, pp.1119-1152, 2013.

, Impact of meriolins, a new class of cyclin-dependent kinase inhibitors, on malignant glioma proliferation and neo-angiogenesis

M. Jarry, C. Lecointre, C. Malleval, L. Desrues, M. T. Schouft et al., Neuro Oncol, vol.16, issue.11, pp.1484-98, 2014.

M. Dubois, L. Joncour, V. Tonon, M. C. Anouar, Y. Proust et al., PLoS One, vol.9, issue.12, p.113533, 2014.

, Signaling switch of the urotensin II vasosactive peptide GPCR: Prototypic chemotaxic mechanism in glioma

C. Lecointre, L. Desrues, J. E. Joubert, N. Perzo, P. O. Guichet et al., , 2014.

, Acute exposure of cerebellar granule neurons to ethanol suppresses stress, LLC 2010 References Acquaah-Mensah GK, Leslie SW, Kehrer JP, 2001.

, Toxicol Appl Pharmacol, vol.175, pp.10-18

W. A. Banks, A. J. Kastin, G. Komaki, and A. Arimura, Pituitary adenylate cyclase activating polypeptide (PACAP) can cross the vascular component of the blood-testis barrier in the mouse, J Androl, vol.14, pp.170-173, 1993.

M. Basille, A. Falluel-morel, D. Vaudry, A. N. Fournier, A. Freger et al., Ontogeny of PACAP receptors in the human cerebellum: perspectives of therapeutic applications, Regul Pept, vol.137, pp.27-33, 2006.
URL : https://hal.archives-ouvertes.fr/pasteur-00820022

A. Belmeguenai, P. Botta, J. T. Weber, M. Carta, D. Ruiter et al., Alcohol impairs long-term depression at the cerebellar parallel fiber-Purkinje cell synapse, J Neurophysiol, vol.100, pp.3167-3174, 2008.

S. V. Bhave and P. L. Hoffman, Phosphatidylinositol 3'-OH kinase and protein kinase A pathways mediate the anti-apoptotic effect of pituitary adenylyl cyclase-activating polypeptide in cultured cerebellar granule neurons: modulation by ethanol, J Neurochem, vol.88, pp.359-369, 2004.

S. Bourgault, D. Vaudry, B. Botia, A. Couvineau, M. Laburthe et al., Novel stable PACAP analogs with potent activity towards the PAC1 receptor, Peptides, vol.29, pp.919-932, 2008.

G. A. Chandorkar, C. Ampasavate, J. F. Stobaugh, and K. L. Audus, Peptide transport and metabolism across the placenta, Adv Drug Deliv Rev, vol.38, pp.59-67, 1999.

S. L. Chao, J. M. Moss, and G. J. Harry, Lead-induced alterations of apoptosis and neurotrophic factor mRNA in the developing rat cortex, hippocampus, and cerebellum, J Biochem Mol Toxicol, vol.21, pp.265-272, 2007.

M. D. Cornelius, L. Goldshmidt, P. M. Taylor, and N. L. Day, Prenatal alcohol use among teenagers: effects on neonatal outcomes, Alcohol Clin Exp Res, vol.23, pp.1238-1244, 1999.

M. Endres, S. Namura, M. Shimizu-sasamata, C. Waeber, L. Zhang et al., Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family, J Cereb Blood Flow Metab, vol.18, pp.238-247, 1998.

E. Esneault, V. Castagne, P. Moser, C. Bonny, and M. Bernaudin, D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats, Neuroscience, vol.152, pp.308-320, 2008.

A. Falluel-morel, A. N. Vaudry, D. Basille, M. Fontaine, M. Fournier et al., Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells, J Neurochem, vol.91, pp.1231-1243, 2004.
URL : https://hal.archives-ouvertes.fr/pasteur-00820050

R. L. Floyd, M. J. O'connor, R. J. Sokol, J. Bertrand, and J. F. Cordero, Recognition and prevention of fetal alcohol syndrome, Obstet Gynecol, vol.106, pp.1059-1064, 2005.

Y. Ge, S. M. Belcher, D. R. Pierce, and K. E. Light, Altered expression of Bcl2, Bad and Bax mRNA occurs in the rat cerebellum within hours after ethanol exposure on postnatal day 4 but not on postnatal day 9, Mol Brain Res, vol.129, pp.124-134, 2004.

B. J. Gonzalez, M. Basille, D. Vaudry, A. Fournier, and H. Vaudry, Pituitary adenylate cyclase-activating polypeptide promotes cell survival and neurite outgrowth in rat cerebellar neuroblasts, Neuroscience, vol.78, pp.419-430, 1997.

C. Guerri, Mechanisms involved in central nervous system dysfunctions induced by prenatal ethanol exposure, Neurotox Res, vol.4, pp.327-335, 2002.

J. Y. Han, Y. Joo, Y. S. Kim, Y. K. Lee, H. J. Kim et al., Ethanol induces cell death by activating caspase-3 in the rat cerebral cortex, Mol Cells, vol.20, pp.189-195, 2005.

H. Hashimoto, N. Shintani, K. Tanaka, W. Mori, M. Hirose et al., Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP), Proc Natl Acad Sci, vol.98, pp.13355-13360, 2001.

C. Ikonomidou, P. Bittigau, M. J. Ishimaru, D. F. Wozniak, C. Koch et al., Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome, Science, vol.287, pp.1056-1060, 2000.

K. L. Jones, D. W. Smith, C. N. Ulleland, and P. Streissguth, Pattern of malformation in offspring of chronic alcoholic mothers, Lancet, vol.1, pp.1267-1271, 1973.

H. Komuro and P. Rakic, Distinct modes of neuronal migration in different domains of developing cerebellar cortex, J Neurosci, vol.18, pp.1478-1490, 1998.

T. Kondo, T. Tominaga, M. Ichikawa, and T. Iijima, Differential alteration of hippocampal synaptic strength induced by pituitary adenylate cyclase activating polypeptide-38 (PACAP-38), Neurosci Lett, vol.221, pp.189-192, 1997.

Y. Masuo, J. Noguchi, S. Morita, and Y. Matsumoto, Effects of intracerebroventricular administration of pituitary adenylate cyclase-activating polypeptide (PACAP) on the motor activity and reserpine-induced hypothermia in murines, Brain Res, vol.700, pp.219-226, 1995.

A. Miyata, A. Arimura, R. R. Dahl, N. Minamino, A. Uehara et al., Isolation of a novel 38 residuehypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells, Biochem Biophys Res Commun, vol.164, pp.567-574, 1989.

T. Miyata, T. Maeda, and J. E. Lee, NeuroD is required for differentiation of the granule cells in the cerebellum and hippocampus, Genes Dev, vol.13, pp.1647-1652, 1999.

M. Molinari and M. G. Leggio, Cerebellar information processing and visuospatial functions, Cerebellum, vol.6, pp.214-220, 2007.

H. S. Nielsen, J. Hannibal, and J. Fahrenkrug, Expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the postnatal and adult rat cerebellar cortex, Neuroreport, vol.9, pp.2639-2642, 1998.

L. Petrosini, M. G. Leggio, and M. Molinari, The cerebellum in the spatial problem solving: a co-star or a guest star, Prog Neurobiol, vol.56, pp.191-210, 1998.

S. H. Poggi, K. Goodwin, J. M. Hill, D. E. Brenneman, E. Tendi et al., The role of activity-dependent neuroprotective protein in a mouse model of fetal alcohol syndrome, Am J Obstet Gynecol, vol.189, pp.790-793, 2003.

V. Ramachandran, L. T. Watts, S. K. Maffi, J. Chen, S. Schenker et al., Ethanol-induced oxidative stress precedes mitochondrially mediated apoptotic death of cultured fetal cortical neurons, J Neurosci Res, vol.74, pp.577-588, 2003.

A. E. Ryabinin, K. R. Melia, M. Cole, F. E. Bloom, and M. C. Wilson, Alcohol selectively attenuates stress-induced c-fos expression in rat hippocampus, J Neurosci, vol.15, pp.721-730, 1995.

M. H. Schwab, S. Druffel-augustin, M. Jung, M. Klugmann, A. Bartholomae et al., Neuronal basic helix-loophelix proteins (NEX, neuroD, NDRF): spatiotemporal expression and targeted disruption of the NEX gene in transgenic mice, J Neurosci, vol.18, pp.1408-1418, 1998.

J. Vandesompele, D. Preter, K. Pattyn, F. Poppe, B. Van-roy et al., Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes, Genome Biol, vol.3, 2002.

L. Varecka, C. H. Wu, A. Rotter, and A. Frostholm, GABAA/ benzodiazepine receptor alpha 6 subunit mRNA in granule cells of the cerebellar cortex and cochlear nuclei: expression in developing and mutant mice, J Comp Neurol, vol.339, pp.341-352, 1994.

D. Vaudry, B. J. Gonzalez, M. Basille, A. Fournier, and H. Vaudry, Neurotrophic activity of pituitary adenylate cyclase-activating polypeptide on rat cerebellar cortex during development, Proc Natl Acad Sci, vol.96, pp.9415-9420, 1999.

D. Vaudry, B. J. Gonzalez, M. Basille, T. F. Pamantung, M. Fontaine et al., The neuroprotective effect of pituitary adenylate cyclase-activating polypeptide on cerebellar granule cells is mediated through inhibition of the CED3-related cysteine protease caspase-3/CPP32, Proc Natl Acad Sci, vol.97, pp.13390-13395, 2000.

D. Vaudry, C. Rousselle, M. Basille, A. Falluel-morel, T. F. Pamantung et al., Pituitary adenylate cyclase-activating polypeptide protects rat cerebellar granule neurons against ethanol-induced apoptotic cell death, Proc Natl Acad Sci, vol.99, pp.6398-6403, 2002.

D. Vaudry, A. Falluel-morel, S. Bourgault, M. Basille, D. Burel et al., Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery, Pharmacol Rev, vol.61, pp.283-357, 2009.
URL : https://hal.archives-ouvertes.fr/hal-02058111

M. Villalba, J. Bockaert, and L. Journot, Pituitary adenylate cyclaseactivating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway, J Neurosci, vol.17, pp.83-90, 1997.

C. Young, B. J. Klocke, T. Tenkova, J. Choi, J. Labruyere et al., Ethanol-induced neuronal apoptosis in vivo requires BAX in the developing mouse brain, Cell Death Differ, vol.10, pp.1148-1155, 2003.

T. Zheng, M. R. Santi, P. Bovolin, L. N. Marlier, and D. R. Grayson, Developmental expression of the alpha 6 GABAA receptor subunit mRNA occurs only after cerebellar granule cell migration, Dev Brain Res, vol.75, pp.91-103, 1993.

L. Zhu, C. Tamvakopoulos, D. Xie, J. Dragovic, X. Shen et al., The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38), J Biol Chem, vol.278, pp.22418-22423, 2003.

, Neurotox Res, vol.19, pp.423-434, 2011.

H. Nmr,

, Hz, 1H), 7.48 (s, 1H), vol.7

, HPLC: t R = 20.9 min, purity >93%. MS(ESI+): m/z (%): 279.13 (100

, 829 cm ?1 . 1 H NMR (300 MHz, 65% yield) as a white solid. IR 2931, 1234.

. Hz,

C. Nmr,

, mL) was added to the previous solution, and the resulting reaction mixture was stirred for 12 h at rt and 1 h under reflux (for a complete conversion). Thereafter, the mixture was cooled to rt and concentrated. The residue was filtered over a silica gel pad (cyclohexane/EtOAc 1:1 then EtOAc) to afford 8 (73 mg, 0.15 mmol, 60%) as a white solid, The resulting mixture was stirred at 0°C for 15 min and at rt for further 15 min. A solution of the benzyl bromide 2 (97 mg, 0.28 mmol, 1.1 equiv) in dry DME, vol.7, p.1228, 1599.

D. +27°, , vol.3

, -tert-Butyl ethoxycarbamate)-2-chloroqui-(28 mg, 0.05 mmol, yield 93%), Calc. for C 22 H 21 ClN 5 O 5 : 470.1231; found: 470.1237. (S)-7, vol.3347, pp.1164-1165, 0200.

J. Mhz-;-d, CDCl 3 ) ? 7.95 (s, 1H), 7.86 (d, J = 9, vol.7, p.61

, Hz, 1H), 5.24 (d, J = 15.6 Hz, 1H), 5.15 (d, J = 16, Hz, 1H), 7.34 (dd, J = 2.4, 9.2 Hz, 1H), 7.02 (d, J = 2.4 Hz, 1H), 6.59 (d, J = 7.2 Hz, 1H), 5.58 (d, J = 16.1 Hz, 1H), 5.42 (d, J = 15

D. +27°, HRMS (ESI+): Calc. for C 27 H

, Bioconjugate Chemistry Article dx, Bioconjugate Chem, vol.24, pp.1119-1133, 2013.

M. E. Wall, C. M. Wani, K. H. Cook, A. T. Mcphail, and G. A. Sim, Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate, J. Am. Chem. Soc, vol.88, pp.3888-3890, 1966.

Y. Pommier, DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition, Chem. Rev, vol.109, 2009.

S. Negoro, M. Fukuoka, N. Masuda, M. Takada, Y. Kusunoki et al., , 1991.

, J. Natl. Cancer Inst, vol.83, pp.1164-1168

Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato, Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11, Cancer Res, vol.51, pp.4187-4191, 1991.

W. D. Kingsburry, J. C. Boehm, D. R. Jakas, K. G. Holden, S. M. Hetch et al., Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity, J. Med. Chem, vol.34, pp.98-107, 1991.

M. S. Goncalves, Fluorescent labeling of biomolecules with organic probes, Chem. Rev, vol.109, pp.190-212, 2009.

R. J. Middleton and B. Kellam, Fluorophore-tagged GPCR ligands, Curr. Opin. Chem. Biol, vol.9, pp.517-525, 2005.

D. Alonso, H. Vazquez-villa, A. M. Gamo, M. F. Martínez-esper, M. Tortosa et al., Development of fluorescent ligands for the human 5-HT1A receptor, ACS Med. Chem. Lett, vol.1, pp.249-253, 2010.

O. Redy and D. Shabat, Modular theranosticprodrug based on a FRET-activated self-immolative linker, J. Controlled Release, vol.164, pp.276-282, 2012.

Y. Liu, W. Dai, J. L. Tian, G. Yank, X. Feng et al., Synthesis and insecticidal activities of novel spin-labeled derivatives of camptothecin, Heteroat. Chem, vol.22, pp.687-691, 2011.

M. Gao, K. D. Miller, G. W. Sledge, and Q. Zheng, , 2005.

H. R. Hinz, N. J. Harris, B. C. Giovanella, E. L. Ezell, and J. G. Liehr, Stabilities of 3H-and 2H-labelled camptothecins, J. Label. Compd. Radiopharm, pp.733-742, 1996.

R. P. Verma and C. Hansch, Camptothecins: A SAR/ QSAR Study, Chem. Rev, vol.109, pp.213-235, 2009.

M. Devert, C. Sabot, P. Giboreau, J. Constant, A. E. Greene et al., Total synthesis of (±)-17-norcamptothecin, a novel E-ring modified camptothecin, Tetrahedron, vol.66, pp.7227-7231, 2010.
URL : https://hal.archives-ouvertes.fr/hal-01658636

B. Ziomkowska, S. Kruszewski, R. Siuda, and M. Cyrankiewicz,

I. Chourpa, J. Millot, G. D. Sockalingum, J. Riou, and M. Manfait, , 1998.

M. Kim, K. Ock, K. Cho, S. Joo, and S. Y. Lee, , p.Live, 2012.

W. Weissleder and V. Ntziachristos, Shedding light onto live molecular targets, Nat. Med, vol.9, pp.123-128, 2003.

G. R. Fulmer, A. J. Miller, N. H. Sherden, H. E. Gottlieb, A. Nudelman et al., NMR chemical shifts of trace impurities: common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist, Organometallics, vol.29, p.2176, 2010.

J. Olmsted, Calorimetric determinations of absolute fluorescence quantum yields, J. Phys. Chem, vol.83, pp.2581-2584, 1979.

F. G. Fang, S. Xie, and M. W. Lowery, Catalytic enantioselective synthesis of 20(S)-camptothecin: a practical application of the sharpless asymmetric dihydroxylation reaction, J. Org. Chem, vol.59, pp.6142-6143, 1994.

C. Massif, S. Dautrey, A. Haefele, R. Ziessel, P. Renard et al., New insights into the water-solubilisation of fluorophores by post-synthetic "click" and Sonogashira reactions, Org. Biomol. Chem, vol.10, pp.4330-4336, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00996469

Y. Duan, M. Liu, W. Sun, M. Wang, S. Liu et al., , 2009.

H. Kobayashi, M. Ogawa, R. Alford, P. L. Choyke, and Y. Urano, New strategies for fluorescent probe design in medical diagnostic imaging, Chem. Rev, vol.110, 2010.

D. L. Comins and J. M. Nolan, A practical six-step synthesis of (S)-camptothecin, Org. Lett, vol.3, pp.4255-4257, 2001.

J. Gao, P. Wang, and R. W. Giese, Xanthamide fluorescent dyes, Anal. Chem, vol.74, p.6397, 2012.

, Bioconjugate Chemistry Article dx, Bioconjugate Chem, vol.24, pp.1119-1133, 2013.

A. Nadler, C. Hain, and U. Diederichsen, Histidine analog amino acids providing metal-binding sites derived from bioinorganic model systems, Eur. J. Org. Chem, pp.4593-4599, 2009.

P. G. Reddy, T. V. Pratap, G. D. Kumar, S. K. Mohanty, and S. Baskaran, The Lindlar catalyst revitalized: a highly chemoselective method for the direct conversion of azides to N-(tertbutoxycarbonyl)amines, Eur. J. Org. Chem, pp.3740-3743, 2002.

P. D'arpa and L. F. Liu, Topoisomerase-targeting antitumor drugs, Biochim. Biophys. Acta, vol.989, pp.163-77, 1989.

H. S. Friedman, S. T. Keir, and P. J. Houghton, , pp.2359-62, 2003.

C. Y. Kim, S. J. Lee, S. K. Kim, C. K. Park, K. C. Wang et al., Antitumor activity of CKD-602, a camptothecin derivative, in a mouse glioma model, J. Clin. Neuro. Sci, vol.19, pp.301-305, 2012.

A. Tanizawa, K. W. Kohn, G. Kohlhagen, F. Leteurtre, and Y. Pommier, Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives, Biochemistry, vol.34, pp.7200-7206, 1995.

A. I. Minchinton and I. F. Tannock, Drug penetration in solid tumours, Nat. Rev. Cancer, vol.6, pp.583-592, 2006.

R. H. Grantab and I. F. Tannock, Bioconjugate Chem, vol.24, pp.1119-1133, 2012.

, 1909, 24, 1; (b) Mottram, J. C, G. Munch. Med. Wochenschr, vol.9, p.606, 1936.

D. M. Brizel, S. P. Scully, J. M. Harrelson, L. J. Layfield, J. M. Bean et al., J. Clin. Oncol, vol.56, p.427, 1996.

P. Vaupel, O. Thew, G. L. Sannazzari, U. Ricardi, A. R. Filippi et al., J. Radiother. Oncol, vol.18, p.18, 2001.

M. Bock, M. Hoffer, and E. Grunberg, J. Med. Chem, vol.11, issue.587, p.17, 1961.

S. Nakamura, Pharm. Bull, vol.3, p.379, 1955.

A. Nunn, K. Linder, H. W. Strauss, L. Mei, Y. Wang et al., Eur. J. Nucl. Med, p.50, 1995.

H. Huang, H. Zhou, Z. Li, X. Wang, and T. Chu, Bioorg. Med. Chem. Lett, p.172, 2012.

K. E. Linder, Y. W. Chan, J. E. Cyr, D. P. Nowotnik, W. C. Eckelman et al., Bioconjugate Chem, p.326, 1993.

R. Neumeier, W. Kramp, and H. Macke, Eur. Patent Appl. 0417, vol.870, p.2, 1990.

R. F. Schneider, E. L. Engelhardt, C. C. Stobbe, M. C. Fenning, J. D. Chapman et al., J. Labelled Compd. Radiopharm, vol.32, p.1764, 1991.

J. R. Ballinger, J. W. Kee, A. M. Rauth, G. Mees, R. Dierckx et al., C Eur. J. Nucl. Med. Mol. Imaging, p.1674, 1023.

M. V. Cantorias, R. C. Howell, L. Todaro, J. E. Cyr, D. Berndorff et al., Inorg. Chem, vol.46, p.7326, 2007.

S. Liu and D. S. Edwards, Chem. Rev, vol.99, p.2235, 1999.

Z. Su, X. Zhang, J. R. Ballinger, A. M. Rauth, A. Pollak et al., Bioconjugate Chem, vol.10, p.401, 1999.

M. B. Mallia, S. Subramanian, A. Mathur, H. D. Sarma, M. Venkatesh et al., J. Labelled Compd. Radiopharm, vol.51, p.535, 2008.

M. P. Hay, W. R. Wilson, J. W. Moselen, B. D. Palmer, and W. A. Denny, J. Med. Chem, vol.37, p.381, 1994.

S. K. Meegalla, K. Plössl, M. Kung, S. Chumpradit, D. A. Stevenson et al., J. Med. Chem, vol.40, p.9, 1997.

, The human glioblastoma cell line T98 was obtained from the American Type Culture Collection

, 2 mM L-glutamine and 100 U/ml penicillin/streptomycin (Gibco, Fischer Scientific, Illkirch, France) at 37°C in a humidified 5% CO 2 incubator, The T98 cells were maintained in HAM-F12

D. A. Wainwright, P. Nigam, B. Thaci, M. Dey, and M. S. Lesniak, Expert Opin. Emerg Drugs, vol.17, p.181, 2012.

L. Yang, C. Lin, L. Wang, H. Guo, X. Wang et al., Cell. Res, vol.318, p.2417, 2012.

P. E. Valk, C. A. Mathis, M. D. Prados, J. C. Gilbert, and T. F. Budinger, J. Nucl. Med, p.2133, 1992.

K. A. Krohn, J. M. Link, R. P. Mason, P. Vera, S. Thureau et al., J. Nucl. Med, vol.49, p.433, 2008.

, HIF-1 binds to the hypoxia responsive element and activates genes involved in angiogenesis, glucose metabolism, cell proliferation, survival and invasion/metastasis. The transient transfection of the Plasmid pHIF1-Luc (0.2 lg/well) or without vector (Mock) was performed using FuGene 6 (1.8 ll/well, Promega) following the manufacturer's protocol. The response of these cells to hypoxia was obtained after 24 or 48, T98 cells were plated in 24-well plates (Costar, 10 Â 10 3 cells/ well) for 24 h before transfection in HAM-F12 (for T98 cells), supplemented with 10% FBS

, Briefly, 24-well plates were washed twice with cold 1Â phosphate-buffered saline (PBS) and 100 ll of 1Â lysis buffer was then added to the cells. Samples were lysed and collected and 20 ll aliquots were assayed using luciferase assay reagent. Luminescence was measured using a Victor V plate reader, Luciferase assay. All cell extracts were prepared and analyzed using the Luciferase Assay System (Promega, Madison, WI)

, -3 MBq) for 1 h then washed twice with cold PBS. Cells radioactivity was measured by a Wallac Wizard 1470 Gamma Counter. Results were expressed as decay, Tracer uptake assay. T98 cells were incubated with 5a,b

, Principles of laboratory animal care' (NIH publication No. 86-23, revised 1985) were strictly followed. Animals were housed four per cage and fed ad libitum. The experiments have been

V. Kersemans, B. Cornelissen, R. Hueting, M. Tredwell, K. Hussien et al., PLoS One, vol.6, 2011.

Y. Joyard, Bioorg. Med. Chem. Lett, vol.23, pp.3704-3708, 2013.

P. Y. Wen and S. Kesari, Malignant Gliomas in Adults, N Engl J Med, vol.359, issue.5, pp.492-507, 2008.

Q. T. Ostrom, H. Gittleman, and P. Farah, CBTRUS statistical report: primary brain and central nervous system. Tumors diagnosed in the United States in 2006-2010, Neuro Oncol, vol.15, issue.2, pp.1-56, 2013.

D. N. Louis, H. Ohgaki, and O. D. Wiestler, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, vol.114, issue.2, pp.97-109, 2007.

N. Shinojima, K. Tada, and S. Shiraishi, Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res, vol.63, issue.20, pp.6962-6970, 2003.

P. Y. Wen and A. A. Brandes, Treatment of recurrent high-grade gliomas, Curr Opin Neurol, vol.22, issue.6, pp.657-664, 2009.

A. Deshpande, P. Sicinski, and P. W. Hinds, Cyclins and cdks in development and cancer: a perspective, Oncogene, vol.24, issue.17, pp.2909-2915, 2005.

M. Malumbres and M. Barbacid, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, vol.9, issue.3, pp.153-166, 2009.

J. Jen, J. W. Harper, and S. H. Bigner, Deletion of p16 and p15 genes in brain tumors, Cancer Res, vol.54, issue.24, pp.6353-6358, 1994.

J. He, J. R. Allen, and V. P. Collins, CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines, Cancer Res, vol.54, issue.22, pp.5804-5807, 1994.

K. Ichimura, E. E. Schmidt, and H. M. Goike, Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene, Oncogene, vol.13, issue.5, pp.1065-1072, 1996.

K. Ueki, Y. Ono, and J. W. Henson, CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated, Cancer Res, vol.56, issue.1, pp.150-153, 1996.

D. A. Solomon, J. Kim, and W. Jean, Conspirators in a capital crime: co-deletion of p18INK4c and p16INK4a/p14ARF/p15INK4b in glioblastoma multiforme, Cancer Res, vol.68, issue.21, pp.8657-8660, 2008.

R. Wiedemeyer, C. Brennan, and T. P. Heffernan, Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development, Cancer Cell, vol.13, issue.4, pp.355-364, 2008.

, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, vol.455, issue.7216, pp.1061-1068, 2008.

D. W. Parsons, S. Jones, and X. Zhang, An integrated genomic analysis of human glioblastoma multiforme, Science, vol.321, issue.5897, pp.1807-1812, 2008.

H. Galons, N. Oumata, and L. Meijer, Cyclin-dependent kinase inhibitors: a survey of recent patent literature, Expert Opin Ther Pat, vol.20, issue.3, pp.377-404, 2010.

H. Galons, Introduction for the special issue on kinase inhibitors, Eur J Med Chem, vol.61, p.1, 2013.

G. I. Shapiro, Cyclin-dependent kinase pathways as targets for cancer treatment, J Clin Oncol, vol.24, issue.11, pp.1770-1783, 2006.

M. Noble, J. A. Endicott, and L. N. Johnson, Protein kinase inhibitors: insights into drug design from structure, Science, vol.303, issue.5665, pp.1800-1805, 2004.

J. J. Luke, D. 'adamo, D. R. Dickson, and M. A. , The cyclin-dependent kinase inhibitor flavopiridol potentiates doxorubicin efficacy in advanced sarcomas: preclinical investigations and results of a phase I dose-escalation clinical trial, Clin Cancer Res, vol.18, issue.9, pp.2638-2647, 2012.

M. A. Dickson, M. A. Shah, and D. Rathkopf, A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol, Cancer Chemother Pharmacol, 2010.

S. Lapenna and A. Giordano, Cell cycle kinases as therapeutic targets for cancer, Nat Rev Drug Discov, vol.8, issue.7, pp.547-566, 2009.

K. Bettayeb, O. M. Tirado, and S. Marionneau-lambot, Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases, Cancer Res, vol.67, issue.17, pp.8325-8334, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00171068

A. Echalier, K. Bettayeb, and Y. Ferandin, Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex, J Med Chem, vol.51, issue.4, pp.737-751, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00319787

L. H. Franco, E. B. Joffé, and L. Puricelli, Indole alkaloids from the tunicate Aplidium meridianum, J Nat Prod, vol.61, issue.9, pp.1130-1132, 1998.

N. B. Perry, L. Ettouati, and M. Litaudon, Alkaloids from the Antarctic sponge Kirkpatrickia varialosa. I: Variolin B, a new antitumour and antiviral compound, Tetrahedron, vol.50, issue.13, pp.3987-3992, 1994.
URL : https://hal.archives-ouvertes.fr/hal-01649341

G. Trimurtulu, D. J. Faulkner, and N. B. Perry, Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: Variolin A and N(3 ? )-methyl tetrahydrovariolin B, Tetrahedron, vol.50, issue.13, pp.3993-4000, 1994.
URL : https://hal.archives-ouvertes.fr/hal-01649341

M. Gompel, M. Leost, and E. B. De-kier-joffe, Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum, Bioorg Med Chem Lett, vol.14, issue.7, pp.1703-1707, 2004.
URL : https://hal.archives-ouvertes.fr/hal-00020119

M. Simone, E. Erba, and G. Damia, Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclindependent kinase inhibitor activity, Eur J Cancer, vol.41, issue.15, pp.2366-2377, 2005.

H. Castel, M. Diallo, and D. Chatenet, Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes, J Neurochem, vol.99, issue.2, pp.582-595, 2006.
URL : https://hal.archives-ouvertes.fr/hal-01960748

T. Lefebvre, B. J. Gonzalez, and D. Vaudry, Paradoxical effect of ethanol on potassium channel currents and cell survival in cerebellar granule neurons, J Neurochem, vol.110, issue.3, pp.976-989, 2009.
URL : https://hal.archives-ouvertes.fr/pasteur-00819661

G. Kroemer and J. C. Reed, Mitochondrial control of cell death, Nat Med, vol.6, issue.5, pp.513-519, 2000.

L. Taillandier, L. Antunes, and K. S. Angioi-duprez, Models for neurooncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice, J Neurosci Methods, vol.125, issue.1 -2, pp.147-157, 2003.

U. E. Gasser and M. E. Hatten, Neuron-glia interactions of rat hippocampal cells in vitro: glial-guided neuronal migration and neuronal regulation of glial differentiation, J Neurosci, vol.10, issue.4, pp.1276-1285, 1990.

L. C. Wang, D. H. Baird, and M. E. Hatten, Astroglial differentiation is required for support of neurite outgrowth, J Neurosci, vol.14, issue.5, pp.3195-3207, 1994.

Z. Darzynkiewicz, G. Juan, and X. Li, Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis)

, Cytometry, vol.27, issue.1, pp.1-20, 1997.

B. Ehrenberg, V. Montana, and M. D. Wei, Membrane potential can be determined in individual cells from the nernstian distribution of cationic dyes, Biophys J, vol.53, issue.5, pp.785-794, 1988.

L. Galluzzi, I. Vitale, E. Vacchelli, and G. Kroemer, Cell death signaling and anticancer therapy, Front Oncol, vol.1, issue.5, 2011.

F. Folmer, M. Jaspars, and M. Dicato, Marine cytotoxins: callers for the various dances of death, Gastroenterol Hepatol Bed Bench, vol.2, pp.34-50, 2009.

P. Weerasinghe and L. M. Buja, Oncosis: an important non-apoptotic mode of cell death, Exp Mol Pathol, vol.93, issue.3, pp.302-308, 2012.

. Jarry, Antitumoral activity of CDK inhibitor meriolins on glioma Neuro-Oncology

P. A. Janmey, The cytoskeleton and cell signaling: component localization and mechanical coupling, Physiol Rev, vol.78, issue.3, pp.763-781, 1998.

M. Lakshman, V. Subramaniam, and S. Jothy, CD44 negatively regulates apoptosis in murine colonic epithelium via the mitochondrial pathway, Exp Mol Pathol, vol.76, issue.3, pp.196-204, 2004.

R. A. Lockshin and Z. Zakeri, Apoptosis, autophagy, and more, Int J Biochem Cell Biol, vol.36, issue.12, pp.2405-2419, 2004.

H. Jaeschke and J. J. Lemasters, Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury, Gastroenterology, vol.125, issue.4, pp.1246-1257, 2003.

N. Hoa, M. P. Myers, and T. G. Douglass, Molecular mechanisms of paraptosis induction: implications for a non-genetically modified tumor vaccine, PLoS ONE, vol.4, issue.2, p.4631, 2009.

K. Bettayeb, N. Oumata, and A. Echalier, CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases, Oncogene, vol.27, issue.44, pp.5797-5807, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00319794

K. Bettayeb, D. Baunbaek, and C. Delehouze, CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells, Genes Cancer, vol.1, issue.4, pp.369-380, 2010.

D. Cai, K. F. Byth, and G. I. Shapiro, AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9, Cancer Res, vol.66, issue.1, pp.435-444, 2006.

K. Michaud, D. A. Solomon, and E. Oermann, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts, Cancer Res, 2010.

N. Pore, S. Liu, and D. A. Haas-kogan, PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter, Cancer Res, vol.63, issue.1, pp.236-241, 2003.

M. A. Ali, H. Choy, and A. A. Habib, SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor, Neoplasia, vol.9, issue.5, pp.370-381, 2007.

G. Melillo, E. A. Sausville, and K. Cloud, Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes, Cancer Res, 1999.

J. Liebl, S. B. Weitensteiner, and G. Vereb, Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis, J Biol Chem, vol.285, issue.46, pp.35932-35943, 2010.

S. Zahler, J. Liebl, and . Fü-rst-r, Anti-angiogenic potential of small molecular inhibitors of cyclin dependent kinases in vitro, Angiogenesis, vol.13, issue.3, pp.239-249, 2010.

E. S. Oz, E. Aydemir, and K. F??k?n, DMSO exhibits similar cytotoxicity effects to thalidomide in mouse breast cancer cells, Oncol Lett, vol.3, issue.4, pp.927-929, 2012.

K. Takase, M. Sawai, and K. Yamamoto, Reversible G1 arrest induced by dimethyl sulfoxide in human lymphoid cell lines: kinetics of the arrest and expression of the cell cycle marker proliferating cell nuclear antigen in Raji cells, Cell Growth Differ, vol.3, issue.8, pp.515-521, 1992.